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ABSTRACT
Depression is the leading cause of disability worldwide. Disorders of the brain,
including depression, are notoriously difficult to treat because the basic pathology
underlying behavioral outcomes remains undefined. Robust chemical biomarkers of these
diseases have not been identified, nor are there reliable methods to measure brain
chemicals. Depression is associated with chemical and inflammatory changes in the brain
that are predicted to contribute to the pathology. By studying the serotonin and histamine
systems we aim to better define the neurochemical basis of depression. Serotonin has
long been hypothesized to play a role in depression since selective serotonin reuptake
inhibitors (SSRIs) are the frontline treatment for depression. Histamine has a wellestablished role in peripheral inflammation and novel data from the Hashemi lab showing
that histamine release inhibits serotonin signaling justifies the need to consider the two
neurotransmitters in tandem. In this work, fast-scan cyclic voltammetry (FSCV)/fast-scan
controlled adsorption voltammetry (FSCAV) were used to measure serotonin
release/reuptake and ambient concentration in the hippocampus and simultaneously
measure histamine and serotonin in the posterior hypothalamus of rodents (both male and
female). I found that both serotonin and histamine signals are consistent across the sexes,
however, pharmacological intervention does tease out some differences in the
neurochemical systems. Next, I employed a SSRI resistant mouse model (SERT Met172)
to study how commonly prescribed SSRIs interact with serotonin. Models of acute
(peripheral injection of lipopolysaccharide) or chronic (chronic mild stress and high fat
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diet (45 kcal % fat)) neuroinflammation were applied to assess effects on serotonin and
histamine. Biochemical (for inflammation) and behavioral (for depression) analysis were
correlated with neurochemical measurements. The data suggested that inflammation
corresponds to increased histamine release, thus increased serotonin inhibition. I also
found that the capacity of SSRIs to increase extracellular serotonin by inhibiting
serotonin transporters (SERTs) was reduced in both inflammation models. However, by
inhibiting histamine synthesis, the ability of SSRIs to increase extracellular serotonin was
restored. My results suggest that histamine plays a fundamental role in modulating
serotonin during inflammation. This deeper insight into the neurochemical basis of
depressive illness shines a spotlight on histamine as a novel therapeutic target.
.
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CHAPTER 1
GENERAL INTRODUCTION1
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Portions of this chapter have been adapted with permission from previously
submitted/published works.
1. Hersey, M., Hashemi, P., Reagan, L. (2020). Integrating the Monoamine and Cytokine
Hypotheses of Depression: Analysis at origins and consequences for the hippocampus.
European Journal of Neuroscience. [in preparation].
2. Hersey, M., Berger, S. N., Holmes, J., West, A., & Hashemi, P. (2018). Recent
Developments in Carbon Sensors for At-Source Electroanalysis. Analytical Chemistry,
91(1), 27-43.
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1.0

Abstract
Psychiatric diseases, like depression, largely affect the central nervous system

(CNS). While the underlying neuropathology of depressive illness remains to be
elucidated, several hypotheses have been offered to underpin the disease, including the
monoamine and cytokine hypotheses. Studying the brain is difficult because of the
delicate nature of the tissue and the need to analyze without disturbing/damaging
function. Carbon-based electrochemical sensors offer a versatile, chemically functional,
and

bio-compatible

platform

for

detecting

a

variety

of

analytes

including

neurotransmitters in vivo. By applying the electroanalytical technique fast-scan cyclic
voltammetry (FSCV) at carbon fiber microelectrodes (CFMs), some analytes of interest,
like neurotransmitters implicated in depression (serotonin and histamine), can be
electroanalyzed, in real time. Herein I introduce the neurochemistry of depression and the
electrochemical tools used in this thesis to study the underlying intricacies of this
disorder.
1.1

Introduction to Neurochemistry
Depression is the leading cause of disability worldwide, impacting more than 300

million people. In addition, the incidence of depression appears to be increasing, as the
number of people seeking treatment for depression has tripled in the last ten years
(Furtado and Katzman, 2015; World Health Organization, 2018). Diagnosis of depression
is based on persistent cognitive, affective and behavioral symptoms like depressed mood
and anhedonia (American Psychiatric Association, 2013). Currently, the underlying
neuroplathological mechanisms responsible for the development and progression of
depressive illness remain equivocal. This is because there are no well-established
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biomarkers for the disease, the variety of symptoms, and the limited ability to study the
human brain at the circuit or synaptic level in real time. This limitation in knowledge is
why the current theories of depression, as described by Mahar et al., employ the study of
a plethora of evolutionary, environmental, social, cognitive, behavioral, biochemical, and
genetic factors (Mahar et al., 2014). For how can we expect to diagnose, explain, and
treat a disease we do not understand?
There are many identified depression etiologies but one commonly accepted one
is stress, real or perceived threats to homeostasis, that are predicted to play a fundamental
role in depression pathology (Firk and Markus, 2007; Kendler et al., 2010). In fact,
evidence suggests that depression may be linked to an overactive stress response due to
chronic activation of stress pathways. The stress response consists of two circuits: the
hypothalamic-pituitary-adrenal (HPA) axis (or the corticotropin releasing hormone
system) and the sympathomedullary axis (or the locus coeruleus-norepinephrine (LC-NE)
system) (Chrousos, 1998; McEwen, 1998; Meaney, 2001). Stress activates the HPA axis
causing the release of corticotrophin releasing hormone (CRH; also known as
corticotrophin releasing factor; CRF) from the hypothalamus. Adrenocorticotropic
hormone (ACTH) is then released from the anterior pituitary gland, further triggering the
adrenal cortex to release glucocorticoids (GCs: cortisol in primates; corticosterone in
rodents),

which

can

increase

release

of

catecholamines.

Dysregulation

or

desensitization/resistance to GCs during the stress response, perhaps due to chronic stress
exposure, has been hypothesized to play a role in depression pathology (Lupien et al.,
2009). Over activation of the LC-NE pathway has been linked to anxiety, depression, and
other psychiatric diseases (Melia and Duman, 1991). Overall, it is believed that this

3

continued exposure to stress and/or stress exposure to these systems results in increased
risk of pathology (McEwen, 1998).
Functionally, because we are challenged in our understanding of the molecular
regulation of mood, hypotheses to explain the chemical dysfunction underlying
depression are limited. The popular, monoamine hypothesis of depression (Belmaker and
Agam, 2008; Krishnan and Nestler, 2008), proposes that three monoamine
neurotransmitters, namely norepinephrine (NE), dopamine (DA), and serotonin (5hydroxytryptamine, 5HT) work together to regulate mood. During depression, these
monoamines are believed to be dysregulated, with a particular notion that extracellular
5HT levels are lower (Asberg et al., 1976b; Asberg et al., 1976a; Owens and Nemeroff,
1994). This theory was precipitated by some studies that found monoamines and their
metabolites to be decreased in the blood, urine, and cerebral spinal fluid (CSF) of
depressed individuals (Schildkraut, 1965; Maas, 1978; Mann, 1979; Maugh, 1981;
Oreland et al., 1981). Other studies have shown that tryptophan depletion can cause
reemergence of depression symptoms in patients (Delgado et al., 1999; Neumeister et al.,
2004). The monoamine hypothesis facilitated antidepressant pharmacotherapies to target
monoaminergic systems. For example, selective serotonin reuptake inhibitors (SSRIs),
inhibit 5HT reuptake, with the goal of increasing the extracellular levels of this
messenger. SSRIs show only modest clinical success and as such, recently, SSRIs have
fallen out of favor with the scientific community (Anderson, 1998; Arroll et al., 2005;
Trivedi et al., 2006; Guo and Lu, 2014). In addition to the modest clinical efficacy
(effective in 26-36 % of patients), SSRI therapy is often associated with delayed clinical
efficacy and harsh side effects (Trivedi et al., 2006; Holtzheimer and Mayberg, 2011).
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SSRIs, common antidepressants prescribed today, increase 5HT concentrations
predictably resulting in antidepressant activity/efficacy (Åberg-Wistedt, 1989).
Grandjean et al. was able to show that the blunting of dorsal raphe nucleus (RN; site of
5HT cell bodies) output following acute stress could be ameliorated with the SSRI
fluoxetine (Grandjean et al., 2019). It is additionally thought that SSRIs may revive
neurogenesis and developmental plasticity via increasing synaptic concentrations of 5HT
(Vetencourt et al., 2008; Kraus et al., 2017). SSRI administration has also been linked to
5HT modulation of glutamate transmission (NMDA receptor dependent plasticity)
(Bennett and Maxwell, 2010; Sanacora et al., 2012) and enhanced brain-derived
neurotrophic factor (BDNF) expression and activity (Mattson et al., 2004). Many clinical
studies have found that there are several limitations associated with the use of SSRIs in
patients with depressive illness: most notably the delay in efficacy and the lack of
therapeutic effects in most patients. It is thought that the delayed effects may be the result
of long-term neuroplasticity deficits that can only be restored by chronic treatment with
SSRIs (Blier and De Montigny, 1994; Olivier, 2015). Together these results suggest that
acute treatment is insufficient to induce the synaptic changes that allow antidepressants to
effectively manage depressive symptoms. However, with chronic treatment variability in
biochemical response may be increased and may contribute to the number of individuals
that do not respond to SSRIs.
Even though there is quite some disagreement in the literature about the mode of
action of SSRIs, SSRIs are efficacious for a subset of patients. However, it is critical to
correctly define the role of 5HT, as well as other monoamines, in depression before
shifting pharmacological gears in the identification and development of potential
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strategies that may prove to be more efficacious in a broader population of patents with
depressive illness.
Limitations of the monoamine hypothesis lead researchers to believe that
monoamines, alone, cannot be responsible for depressive illness. Beyond monoamines,
evidence continues to support a critical role for pro-inflammatory cytokines in the
development and progression of depressive illness, which has led to a newer, cytokine
hypothesis of depression (Haase and Brown, 2015). For a long time the brain was
believed to be immuno-privileged due to the protection that the blood-brain barrier
(BBB) affords (Schiepers et al., 2005). However, researchers now believe that increases
in immune activity and pro-inflammatory cytokine release in the periphery can directly
influence brain chemistry. These proinflammatory markers are predicted to induce
changes in the CNS that can result in psychiatric diseases like depression (Yirmiya et al.,
1999; Raison et al., 2006; Dantzer et al., 2008; Maes et al., 2009; Miller et al., 2009). In
further support of the cytokine hypothesis, increased immune activity has been linked to
“sickness behavior” with symptoms similar to depression symptoms including anxiety,
anhedonia, fatigue, sleep impairments, and cognitive dysfunction (Dantzer, 2001;
Capuron and Miller, 2011). Drugs like infliximab, a tumor necrosis factor (TNF)-α
antagonist, may be effective approaches to treat depression symptoms in patients with
high levels of inflammation (Raison et al., 2013). Unfortunately, even though some
inflammation-targeting treatments have shown promising results, the cytokine hypothesis
alone has not been enough to explain the pathophysiology of depression. Interestingly,
antidepressants that target monoamines, like SSRIs and serotonin-norepinephrine
reuptake inhibitors (SNRIs), have anti-inflammatory properties suggesting that
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monoamine and inflammation paths may overlap (Kubera et al., 2001; Diamond et al.,
2006; Horikawa et al., 2010; Hannestad et al., 2011; Liu et al., 2011).
These observations suggest that the deficits in monoamine activity and
neuroinflammation mediated by pro-inflammatory cytokines may facilitate independent
and also overlapping mechanisms that contribute to the neuropathology of depressive
illness. Accordingly, the focus of my thesis is to merge these two hypotheses with a
specific emphasis on monoamine synthesis centers and the limbic regions they project to.
Inflammation
Immune responses, both innate and acquired, are activated via stress (Chrousos,
2009). In response to stress, GCs promote the release of pro-inflammatory cytokines from
microglial, macrophages, T-cells, and astrocytes (Kinouchi et al., 1991; Nisticò and De
Sarro, 1991; Cunningham Jr and De Souza, 1993; Laflamme and Rivest, 1999; GarcíaBueno et al., 2008). Cytokines mediate the innate immune response, and have been
considered “immunotransmitters” (Dunn, 2006). Further, cytokines and their receptors
are endogenously found in the brain, at low concentrations, during basal conditions in the
absence of inflammation (Schmidt et al., 2014). Importantly, and related to this
discussion, neurological and immune stressors can influence cytokine release and
cytokine receptor concentrations (Anisman et al., 2002). For example, lipopolysaccharide
(LPS) administration increases the proinflammatory cytokines TNF-α, monocyte
chemoattractant protein (MCP)-1, and interleukin (IL)-1β in the liver, serum, and brain
within one hour (Quan and Banks, 2007; Qin et al., 2008). Of note, these increases in
cytokines rapidly return to normal in the liver and serum but can last for much longer
periods in the brain (Qin et al., 2008). These temporal responses are critical since
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cytokines serve an important immune function under healthy conditions but overactivation or impaired regulation of the stress response and the stress-mediated cytokine
release system is likely detrimental. Further, clinically depressed patients have been
shown to have elevated levels of pro-inflammatory cytokines and their receptors in blood
and CSF (Maes et al., 1999; Miller et al., 2009). For example, many studies have
inconsistently shown that depressed patients, compared to healthy controls, have elevated
IL-1β, IL-2, IL-5 IL-6, IL-13, TNF-α, interferon (INF)- γ, C-reactive protein (CRP), Tolllike receptor 3 (TLR3), TLR4, and PGE2 (Maes, 1995; Dantzer et al., 2008; Dowlati et
al., 2010; Felger and Lotrich, 2013; Lichtblau et al., 2013; Hodes et al., 2015; Miller and
Raison, 2016) as well as increased numbers of circulating leukocytes (Maes et al., 1992).
In fact, IL-1β, IL-6, TNF-α, and CRP are considered fairly reliable biomarkers for
inflammation-associated depression (Miller et al., 2009; Miller and Raison, 2016).
In further support of the cytokine hypothesis, increases in immune activity
(cytokines, etc.) induces “sickness behavior” akin to that seen with depression (Dantzer et
al., 2008; O'Connor et al., 2009; Capuron and Miller, 2011). Administration of a low
dose of LPS to rats, elicited depressed mood, memory impairments, and anxiety in the
absence of symptoms of physical illness (Yirmiya, 1996). Further, the intensity of LPSinduced changes in cognitive and emotional qualities correlates to the levels of
proinflammatory markers, IL-1 and TNF-α (Yirmiya et al., 2000). In patients that
undergo cytokine immunotherapies, such as that seen with some cancers and viral
disease, depression symptoms frequently present (Capuron et al., 2002; Capuron and
Dantzer, 2003). On the other hand, IL-10, an anti-inflammatory cytokine, can block
depressive-like behaviors induced by elevated IL-1 and/or LPS administration (Kent et
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al., 1992; Bluthe et al., 1995; Dantzer et al., 2008). Additionally, blockade of these
cytokine pathways, with the cyclooxygenase 2 (COX-2) inhibitors (Celecoxib) or TNF-α
blockers for example, decreases depressive symptoms (Tyring et al., 2006; Kohler et al.,
2014; Abbott et al., 2015). Overall, targeting impaired/overactive immune activity has
been shown to have antidepressant properties (McNally et al., 2008; Dean and Keshavan,
2017).
Hyperactivity of the HPA axis and the stress-activated immune response may
disrupt necessary mechanisms for negative feedback and has been linked with depression
pathophysiology (Yirmiya, 1996). In fact, individuals at risk of developing depression
(e.g. early life trauma) show elevated immune responses to stressors over individuals that
are considered low risk for depression (Miller and Raison, 2016) thereby highlighting the
importance of the stress-immune balance. Indeed, activation of immune pathways (like
proinflammatory cytokine release) can activate stress pathways, suggesting that the
relationship is bidirectional. Interestingly, this trend that is mirrored in the bidirectional
relationship between the development/risk of depression and the development/risk for
inflammatory diseases like cardiovascular disease, cancer, or diabetes (Aggarwal et al.,
2006; Ridker, 2007; Guo and Lu, 2014). In depression, dysregulation of the immune
response is often seen along with dysregulation of appropriate stress responses,
suggesting a physiological link could be biochemically relevant in depression pathology.
Inflammation’s Role in Psychiatric Disease
Pro-inflammatory cytokines are thought to be implicated in depression by directly
influencing monoaminergic systems (Miller and Raison, 2016). One way is through
activation of p38 mitogen-activated protein kinase (MAPK) by IL-1β or TNF-α, which is
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linked to elevated function and expression of serotonin transporters (SERTs). Further,
this has been shown to decrease extracellular 5HT and increase depressive-like behaviors
(Ramamoorthy et al., 1995; Zhu et al., 2010). Second, inflammation generates reactive
oxygen species (ROS) and reactive nitrogen species (RNS) which decreases the activity
and expression of oxidative stress sensitive enzymes like tetrahydrobiopterin (BH 4)
(Neurauter et al., 2008). BH4 is a co-factor used during synthesis of monoamine
neurotransmitters and has been shown to negatively correlate to CSF IL-6 levels in
patients treated with inflammatory cytokines (Felger et al., 2013). Third, the enzyme
indoleamine 2,3-dioxygenase (IDO) is also activated by inflammation/cytokines and
diverts the metabolism of tryptophan towards kynurenine, or away from 5HT production
and towards production of quinolinic acid, a neurotoxic metabolite (Miller and Raison,
2016). More simply, activation of IDO decreases synthesis of melatonin and 5HT (Müller
and Schwarz, 2007). Interestingly, blocking IDO in mice treated with LPS inhibits the
appearance of depressive-like behaviors (O'Connor et al., 2009). Next, cytokines have
been implicated in the dysregulation of the HPA axis (Holsboer, 2000; Swaab et al.,
2005). Specifically, cytokines can modulate the secretion of ACTH and cortisol
(Besedovsky et al., 1991; Ericsson et al., 1994; Himmerich et al., 2006). Last, following
treatment with SSRIs, plasma cytokines were found to normalize in most patients while
patients who failed to respond to SSRI treatment also maintained elevated plasma
cytokines (O’Brien et al., 2007; Yoshimura et al., 2009; Hannestad et al., 2011).
Collectively, these clinical studies further support the hypothesis that pro-inflammatory
cytokines are a core feature in disease pathology, likely through decreasing synaptic
concentrations of monoamines.
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Anti-inflammatory cytokines may also be important in depression pathology. IL10 is an anti-inflammatory cytokine that inhibits production of pro-inflammatory
cytokines (de Waal Malefyt et al., 1991). Ohgi et al. showed that increasing 5HT levels
through SSRI treatment increases IL-10 (Ohgi et al., 2013). IL-10 cytokine has also been
linked to depressive-like behaviors and to decreased HPA axis reactivity (Mesquita et al.,
2008; Roque et al., 2009). Cytokines, as current research appears to suggest, are
mediating immune dysregulation in the periphery and gaining access to and initiating
changes in the central nervous system.
Immune-CNS Communication via Cytokines
A commonly asked question is how do cytokines, which are fairly large
molecules, move from the periphery to the CNS, which was originally considered
immune-privileged? It has been proposed that the blood brain barrier (BBB) becomes
‘leaky’ following chronic stress (as is seen with chronic depression) and as such it is
possible that cytokines can enter via leaky regions of the BBB (Reader et al., 2015;
Miller and Raison, 2016). Additionally, some cytokines, such as IL-6 and IL-1β, readily
cross the BBB via saturatable transport (Banks, 2005). Once in the brain, these cytokines
can act directly on CNS cells (including neurons) where they have been shown to have
important roles in standard physiological processes including neuronal differentiation,
astrocyte proliferation, temperature regulation, and modulation of pain (Gadient and
Otten, 1997). For example, TNF-α, when administered via intravenous injection, can be
transported into the brain within minutes by TNF receptors acting as transporters (Pan
and Kastin, 2002). This was confirmed by administering TNF-α or LPS to TNF receptor
(1 and 2) double knock out mice, which failed to show significant increases in
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proinflammatory cytokines TNF-α or MCP-1 in the brain (Qin et al., 2007). Another
potential route for entry of cytokines into the CNS is cytokines binding to peripheral
nerves that terminate in the CNS. For example, cytokine release can activate vagus nerve
fibers which can modulate cytokine release in the CNS (from the brainstem and
hypothalamic nuclei as well as modulate ascending catecholaminergic fibers) (Gabellec
et al., 1995; Rothwell and Hopkins, 1995; Dantzer, 2001; Pavlov and Tracey, 2005;
Miller et al., 2009). In support of this concept, subdiaphragmatic vagotomy eliminates
LPS-induced proinflammatory cytokine release in the periphery but did prevent the
development of sickness behavior in rodents (Bluthé et al., 1994; Dantzer et al., 1998;
Luheshi et al., 2000). Yet another pathway through which cytokines may transmit their
signals to the CNS is activation of cells that can cross the BBB. Monocytes have also
been identified as potential players since they can be trafficked into the brain via gaps in
the BBB’s epithelial lining (Gordon and Taylor, 2005; Wohleb et al., 2013). In support of
this concept, recent post-mortem studies of depressed patients, compared to nondepressed controls, show increased recruitment of monocytes into the brain (TorresPlatas et al., 2014). Taken together these data support the hypothesis that peripheral
inflammation is extending to the brain.
Histamine
Another inflammatory mediator is histamine, and while histamine is well known
for its role in peripheral inflammation, it is not known if histamine plays a role in
neuroinflammation (Haas et al., 2008). In the periphery, histamine is released from mast
cells in response to stress or injury, allowing it to act in an immunomodulatory capacity
(Rocklin, 1976; Schwartz et al., 1980). This molecule is also found in platelets,
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neurotrophils, and enterochromaffin-like cells (Rocha et al., 2014). In the CNS, it is
estimated that 50 % of histamine originates from mast cells (Atsushi et al., 1982; Johnson
and Krenger, 1992; Silver et al., 1996) but histamine can also be produced by neurons
and microglia (Katoh et al., 2001; Haas et al., 2008). Further, microglia can also be
activated by histamine to produce pro-inflammatory cytokines (Dong et al., 2014). Such
observations suggest that histamine is uniquely positioned to play a role in
neuroinflammatory processes in the CNS and in the neuropathology observed in
neuropsychiatric disorders.
Neuronal CNS histamine originates in the tuberomammillary nucleus (TMN) of
the hypothalamus. The TMN sends neuronal projections throughout the CNS where
terminal histamine release has a neuromodulatory role (Watanabe et al., 1983; Panula et
al., 1984). Histamine is thought to modulate cognition, arousal, behavior, and hormone
release (Haas et al., 2008). Interestingly, histamine has rapid turnover rates and is
functional state-dependent (i.e. active state vs. sleep state) (Dismukes and Snyder, 1974;
Pollard et al., 1974). Of note, NE, 5HT, and DA release can all be enhanced by activation
of histamine receptors at the LC (Kostopoulos et al., 1988), the RN (Brown et al., 2002),
and the ventral tegmental area (VTA)/substantia nigra (SN) (Airaksinen and Panula,
1988;

Panula

et

al.,

1989),

respectively.

Indeed,

using

microdialysis

and

electrophysiological approaches, Flik et al. demonstrated that histamine modulates NE,
5HT, and DA release in the prefrontal cortex (PFC) (Flik et al., 2015). Additionally,
histamine has been shown using electrophysiology to modulate acetylcholine release
(Baux et al., 1992).
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There are four known histamine receptors (H1R, H2R, H3R, H4R). H1R and H2R
were originally studied for their role in depression but these studies resulted in
inconclusive results (Horovitz et al., 1966; Barnett et al., 1969; Wallach and Hedley,
1979; Katz and Sibel, 1982; Willner, 1984; O'Neill and Gertner, 1986; Noguchi et al.,
1992). The H1R is the target of classic antihistamines (diphenhydramine, etc.) to counter
allergic responses. The H2R is a common target gastric ulcer treatments by inhibiting
gastric acid secretion (ranitidine, etc.). The H3R is of particular interest because it is
commonly found presynaptically and inhibits histamine synthesis (Arrang et al., 1987),
histamine release (Arrang et al., 1987; Van der Werf et al., 1987), GABA release (Garcia
et al., 1997; Yamamoto et al., 1997; Arias‐Montaño et al., 2001), NE release (Schlicker et
al., 1989), 5HT release (Schlicker et al., 1988; Fink et al., 1990; Threlfell et al., 2004;
Hashemi et al., 2011), DA release (Schlicker et al., 1993), and acetylcholine release
(Arrang et al., 1995; Giorgetti et al., 1997; Prast et al., 1999). The H4R was more
recently discovered and is found on immune cells (mast cells, T cells, dendritic cells, etc.)
where it modulates cytokine and chemokine production and release (O'Reilly et al., 2002;
Hofstra et al., 2003). Such observations suggest that H3R and H4R could play important
roles in mediating immune responses in the CNS. Certainly, histamine has recently come
to the forefront as a potentially important player in the delicate balance that is the stressimmune response. Therefore, just like cytokines, histamine could be a potential
contributor to psychiatric disease, and further, a potential target for treatments.
Histamine’s Role in Psychiatric Disease
Like the ‘classic’ monoamines (i.e. 5HT, DA, NE), the role of histamine in the
pathogenesis of depressive illness remains poorly understood (Lamberti et al., 1998; Otte
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et al., 2016). It has, however, been determined that loss of histamine or histamine
receptors produces depressive-like phenotypes (Nath et al., 1988; Song et al., 1996; Ito et
al., 1999; Dai et al., 2004). Histamine neurons from the TMN are sensitive to many
neuroendocrine signals associated with depression (monoamines, steroid hormones,
peptides, antidepressant medication, etc.) (Haas et al., 2008). Moreover, extracellular
histamine and histamine synapses/innervations have been associated with disease and
neuronal survival as they are both shown to be decreased with injury, infection, or
degeneration (Anichtchik et al., 2000; Rocha et al., 2014).
The studies reviewed above provide a framework through which proinflammatory cytokines and histamine may participate in the etiology and progression of
depressive illness, namely through modulation of monoamine synthesis and activity.
Accordingly, the following sections will provide an overview of the monoamine
hypothesis of depression, with an emphasis on potential sites of intersection between
5HT and neuroinflammation.
Serotonin (5HT)
5HT, since its discovery in the 1950s (Twarog and Page, 1953), has been well
researched for its role in stress (Chaouloff et al., 1999) and psychiatric disease (Andrews
et al., 2015). Brain 5HT accounts for only 5 % of the total 5HT in the body as the
majority of 5HT is found in the blood and in the gut (Jacobs and Azmitia, 1992). CNS
5HT has also been implicated in sleep, circadian rhythms, cognition, appetite, motor
activity, and other biological functions (Rueter et al., 1997; Mann, 1999). 5HT is
synthesized from tryptophan in the dorsal raphe nucleus which sends projections
throughout the brain and spinal cord (Descarries et al., 1982), including stress-sensitive
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brain regions like the hippocampus. In fact, 5HT is considered the most widely
distributed neurotransmitter (Steinbusch, 1981) and exerts modulatory actions via volume
transmission (Bunin and Wightman, 1998).
Serotonin’s Role in Psychiatric Disease
During acute stress, 5HT has been shown to increase (De Kloet et al., 1983). In
support of this notion it has been found that HPA axis activation increases 5HT activity
(Rolls, 2000; Lanfumey et al., 2008). Additionally, it has been shown that RN neurons
are activated, following a forced swim test stress or restraint stress (Cullinan et al., 1995).
A proposed mechanism for increased 5HT activity is that GCs increase the activity of
tryptophan hydroxylase (Singh et al., 1990), resulting in increases in 5HT synthesis and
turnover (Chaouloff, 1993). Overall, studies suggest that acute stress increases 5HT
synthesis and release (Anisman, 1982; Chaouloff, 1993). Chronic stress however, is
thought to put long-term strain on the 5HT system that creates deficits in activity and has
been linked to increased sensitivity of the serotonergic system to stressors (Adell et al.,
1988). Stress may also effect intracellular synthesis, vesicular packaging, metabolism
(via monoamine oxidase (MAO)-A), and reuptake of 5HT (Mahar et al., 2014). Many
other factors have been shown to induce changes in the serotonergic system including
diet (tryptophan depletion, fat), gut microbiota, genetics, toxins, exercise, and sleep
(Biggio et al., 1974; Blundell, 1977; Dey et al., 1992; Lopez-Rodriguez et al., 2003;
Meyer-Lindenberg et al., 2006; Slotkin et al., 2008; Yano et al., 2015). For example,
studies have also shown that a tryptophan-depleted diet could elicit depressed mood in
patients in remission (Delgado et al., 1999; Neumeister et al., 2004). Richardson-Jones et
al. also showed that polymorphisms that increased 5HT1A autoreceptor activity impaired
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stress response, and increased depressive-like behaviors as well as decreasing behavioral
effect of SSRIs (Richardson-Jones et al., 2010). Polymorphisms in the promotor region of
the serotonin transporter gene (5HTT) have also been linked to depressive symptoms
following stressful life events (Caspi et al., 2003).
Psychiatric diseases, like depression, result from chronic stress (in addition to
many other factors). In patients with depressive illness, decreases have been seen in
serum 5HT (Bot et al., 2015), the 5HT precursor tryptophan in plasma (Quintana, 1992),
and changes in 5HT metabolites (5-hydroxyindoleacetic acid (5HIAA) concentrations in
CSF (Asberg et al., 1976b; Asberg et al., 1976a; Roy et al., 1989). Changes in the number
or function of 5HT receptors (especially autoreceptors) (Stanley and Mann, 1983; Mann
et al., 1986; Arora and Meltzer, 1989) and 5HT transporters (Stanley et al., 1982; Perry et
al., 1983; Leake et al., 1991) have also been seen (Owens and Nemeroff, 1994).
Serotonin’s Role in Inflammation
There is good agreement on an association between 5HT and inflammation. Early
studies showed that plasma 5HT can suppress immune activity (Devoino et al., 1975;
Pierpaoli and Maestroni, 1978; Bliznakov, 1980), a phenomenon likely mediated by the
5HT uptake system found on macrophages (Roszman and Brooks, 1980). On the other
hand, increases in inflammation, like that following LPS or CRF administration, elevate
5HT turnover, and reduce 5HT synthesis (Dunn and Wang, 1995; Linthorst et al., 1995;
Dunn et al., 1999; Anisman et al., 2005; Capuron and Miller, 2011). These changes are
predicted to further exacerbate depression symptoms linked to decreased 5HT, possibly
via changes in 5HT receptors and transporters in an inflammation-dependent manner
(Anisman et al., 2002; Schiepers et al., 2005). In support of these concepts, rodent studies
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have shown that SERT knockouts exhibit decreased anhedonia and depressive-like
behaviors in response to LPS administration compared to wild-type rodents (Zhu et al.,
2010; van Heesch et al., 2013). This is predicted to be through a cytokine and p38 MAPK
mediated pathway that increases SERT function. As noted above, the inflammationactivated enzyme IDO is a common culprit for linking inflammation and 5HT. Immune
activation of IDO shifts tryptophan metabolism away from 5HT thereby resulting in
decreased 5HT, which could be a core, synaptic deficit associated with depression. Of
note, antidepressants that target 5HT, like SSRIs have been shown to act in an antiinflammatory manor (Kubera et al., 2001; Diamond et al., 2006; Horikawa et al., 2010;
Hannestad et al., 2011; Liu et al., 2011). Ohgi et al. further showed that pretreatment with
SSRIs or SNRIs attenuates LPS-induced pro-inflammatory cytokine release as well as
depressive-like behaviors (Ohgi et al., 2013).
The sections above demonstrate that it has become increasingly clear that
depression pathology is related to monoamine neurotransmitter impairments and over
activation/prolonged activation of the immune response pathway. Which is why key
markers associated with depression in some patients include increased CRP and proinflammatory cytokines in blood or CSF (Maes, 1995; Dantzer et al., 2008; Miller and
Raison, 2016). Schmidt et al. reviewed the potential roles of growth factors like brainderived neurotropic factor (BDNF) or insulin-like growth factor-1 (IGF-1), inflammatory
makers like TNF- α and IL-6 as potential biomarkers for depression but they often lack
sensitivity and specificity (Schmidt et al., 2011). Moving forward, understanding
depression and finding reliable biomarkers, as well as improving treatment options will
be essential towards reducing the lofty physical, emotional, and economic burdens of
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depression on our society. One of the first steps towards this goal is finding a better way
to study 5HT neurochemistry, especially during stress and increased immune activation.
In order to achieve this, I employed electrochemistry.
1.2

Introduction to Electrochemistry
Physiological systems are complex and dynamic. Carbon is an attractive material

for electrochemical analysis due to its many advantageous qualities including availability,
ease of modification, and biocompatibility. Carbon-based sensors have been used
successfully for targeting key organs including the lymph nodes, gut, brain, and skin for a
wide array of analytes. The brain is a particularly challenging to access due to the delicate
nature of the organ, but carbon fiber microelectrodes (CFMs) have been successfully
used for measurements of neurotransmitters and neuromodulators. With carbon-based
sensors, scientists are creating novel electroanalytical devices that are greatly improving
the speed and quality of at-source detection including that of in vivo neurotransmission.
The most popular use of carbon-based sensors paired with electrochemistry in the
brain is to study DA. DA sensing via FSCV is unique in that it can be performed in
awake-behaving animals, while fast voltammetric detection of other analytes is currently
limited to anesthetized animals (Fortin et al., 2015). CFMs can be modified to further
improve sensitivity and selectivity and reduce fouling; one notable modification is
electropolymerizing Nafion and poly(3,4-ethylenedioxythiophene) (PEDOT) polymers
onto the electrode surface for dopamine in vivo (Vreeland et al., 2015). Carbon-based
sensors have also shown promise for long-term implantation. In nonhuman primates,
CFMs were chronically implanted for DA measurements over more than 100 days
(Schwerdt et al., 2017).
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In vivo detection of neurotransmitters other than DA can be challenging primarily
because of structural resemblances and low concentrations of similar analytes. 5HT has
been analyzed using a 5HT-specific waveform (1000 V s−1 scanning from 0.2 V to 1 V to
−0.1 V to 0.2 V) on CFMs modified with Nafion for both stimulated release of 5HT via
FSCV, as well as basal measurements with fast-scan controlled adsorption voltammetry
(FSCAV) (Hashemi et al., 2009; Srejic et al., 2016; Abdalla et al., 2017). For the latter
study, Abdalla et al. employed Nafion-coated CFMs to measure ambient 5HT in vivo in
the hippocampus of mice (Abdalla et al., 2017).
Histamine has also been evaluated in vivo using FSCV, with Nafion-coated CFMs
and a histamine-specific waveform (600 V s−1 scanning from −0.5 V to −0.7 V to 1.1 V
to −0.5 V) (Samaranayake et al., 2015). This waveform is unique in that it allows for
simultaneous detection of histamine and 5HT in the mouse hypothalamus.
Other neurotransmitters and molecules have also been studied with CFMs
including NE (Schmidt et al., 2018), hydrogen peroxide (Meunier et al., 2018), and
adenosine (Ganesana and Venton, 2018). For more information readers are directed to the
recent review by Roberts & Sombers (Roberts and Sombers, 2018). Overall,
measurements in real samples, especially the measurement of neurotransmitters in the
brain, require high sensitivity, stability, and reproducibility which carbon allows. The
work presented here will continue to apply CFMs and electrochemistry to answer
questions about biological function and disease pathology.
In conclusion, electrochemistry offers an advantageous platform from which we
can begin to tease apart how stress and immune activation can induce changes in the
serotonergic system and how these changes may be linked to depression or depressive-
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like behaviors. In this work, I employ an acute inflammation model (systemic
administration of LPS) and chronic inflammation models (chronic mild stress and high
fat diet) to elucidate the links between inflammation and 5HT neurochemistry.
1.3
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CHAPTER 2
GENERAL METHODS2

2

Portions of this chapter have been adapted with permission from previously published
work:
Saylor, R. A.✝, Hersey, M.✝, West, A., Buchanan, A. M., Nijhout, H. F., Reed, M. C.,
Best, J., & Hashemi, P. (2019). In Vivo Serotonin Dynamics in Male and Female Mice:
Determining Effects of Acute Escitalopram Using Fast Scan Cyclic
Voltammetry. Frontiers in Neuroscience, 13, 362.
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2.1

Chemicals and Reagents

Basal Serotonin Calibrating Solutions:
Calibration solutions were prepared by dissolving serotonin hydrochloride
(Sigma–Aldrich Co., St. Louis, MO, USA) in Tris buffer to produce solution
concentration of 10, 25, 50, and 100 nM. Tris buffer consisted of: 15 mM
H2NC(CH2OH)2 HCl, 140 mM NaCl, 3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM
NaH2PO4.H2O, 1.2 mM MgCl2, and 2.0 mM Na2SO4 (Sigma–Aldrich Co., St. Louis,
MO, USA) in deionized water and pH adjusted to 7.4.
Pharmaceutical agents:
Pharmacological agents were prepared as described below. Escitalopram (ESCIT)
oxalate (3, 10, or 30 mg kg-1, Sigma–Aldrich, St. Louis, MO, USA), methiothepin
mesylate salt (0.1 mg kg-1, Sigma–Aldrich, St. Louis, MO, USA), thioperamide maleate
(20 mg kg-1, Sigma Aldrich Co., St. Louis, MO, USA), immepip (5 mg kg-1, Sigma
Aldrich Co., St. Louis, MO, USA), paroxetine hydrochloride (10 mg kg-1 Sigma–Aldrich,
St. Louis, MO, USA), lipopolysaccharide (LPS, 0.2 or 1 mg kg-1, Sigma-Aldrich Co., St.
Louis, MO, USA), α-fluoromethylhistidine (20 mg kg-1, Toronto Research Chemicals
Inc., Toronto, CAN), GBR 12909 (15 mg kg-1, Sigma-Aldrich Co., St. Louis, MO, USA),
desipramine hydrochloride (15 mg kg-1, Sigma-Aldrich Co., St. Louis, MO, USA),
citalopram (5 mg kg-1, Sigma-Aldrich Co., St. Louis, MO, USA), sertraline (10 mg kg-1,
Sigma-Aldrich Co., St. Louis, MO, USA), D22 (0.1 mg kg-1, Sigma-Aldrich Co., St.
Louis, MO, USA), and fluoxetine hydrochloride (10 mg kg-1 Sigma–Aldrich, St. Louis,
MO, USA) were individually dissolved in sterile saline (Hospira, Lake Forest, IL, USA).
Tetrabenazine (10 mg kg-1, Sigma–Aldrich, St. Louis, MO, USA) was dissolved in 10%
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DMSO (Sigma–Aldrich, St. Louis, MO, USA) in sterile saline. All pharmaceutical agents
were administered via intraperitoneal (i.p.) injection at a volume of 5.0 mL kg-1 of animal
weight. Escitalopram oxalate (Sigma-Aldrich Co., St. Louis, MO, USA) at 0.1, 0.5, 1.0
µM solutions was also applied to cell culture samples.
2.2

Electrode Fabrication
Carbon fiber microelectrodes (CFMs) were made as previously described

(Hashemi et al., 2009). Briefly, a single carbon fiber (7 μm, Goodfellow, Corporation,
Coraopolis, PA, USA) was aspirated into a glass capillary (0.6 mm OD, 0.4 mm ID, 10
cm length; A-M Systems, Sequim, WA, US) and sealed under gravity and heat by
vertical pipette puller (Narishige Group, Tokyo, JPN). Exposed fibers were trimmed to
~150 µm under light microscope and silver paint was used to forge an electrical
connection to a connection pin. Finally, electrodes were electrodeposited with Nafion TM
(LQ-1105, Ion Power Solutions, New Castle DE, USA) as previously described (Hashemi
et al., 2009).
2.3

Animal and Surgical Procedures

2.3.1

Animals
All animal procedures and protocols were performed in accordance with

regulations of the Institutional Animal Care and Use Committee (IACUC) at the
University of South Carolina, which operates with accreditation from the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Male and female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA),
6–12 weeks old and weighing 18–30 g, were group housed, with ad libitum access to
food and water, and were kept on a 12 h light/12 h dark cycle (lights off at 7:00 and on at
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19:00). We chose to include mice from this broad age range since we found no statistical
differences in evoked serotonin in mice aged 6–8 and 9–12 weeks (Figure A.1). Female
mice were selected at random, without regard to their estrous cycle. In the estrous cycle
experiments, vaginal smears were collected after the conclusion of the experiment and
cycle determine according to Caligioni (Figure A.2) (Caligioni, 2009). Estrous cycle
determination was limited to a single-day cell analysis at the end of the neurochemical
analysis in order to limit stress to the animal that would likely alter FSCV/FSCAV
serotonergic responses.
A chronic unpredictable mild stress (CMS) paradigm was conducted over a 16week period and based on previously documented models (Papp et al., 1991; Matthews et
al., 1995; Forbes et al., 1996; Mineur et al., 2006). Two to three mild stressors were
performed a day. Stressors included: food or water deprivation, confinement, cage tilt,
soiled cage, light during dark cycle, bedding removal, novel object, handling. All
stressors were stopped during behavior testing and twelve hours leading up to
neurochemical studies.
This work also employed adult SERT Met172 knock in mice on a 129S6/S4
background were backcrossed with C57BL/6J mice. Control or wild type (WT) mice are
C57 mice with 129 wildtype SERT gene (Ile172). Met172, Ile172 mice/WT, and
heterozygous mice, male and female, ages 6-15 weeks, and weighing about 18-30 g, were
housed 5 to a cage with ad libitum access to food and water and were maintained on a 12
h light/12 h dark cycle.
Sprague Dawley rats were purchased from Charles River at 2 months of age
(Charles River Laboratories, Wilmington, MA, USA). Animals were housed individually
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with enrichment on 12 h light/dark cycles with ad libitum access to food and water.
Animals were kept on a “normal chow” diet for one week while habituating upon arrival.
Prior to dietary treatment body weights and blood samples were collected for each rat.
Animals were then randomly selected for either control (15% kcal from fat) or high fat
diet (45 % kcal from fat) (Research Diets Inc., New Brunswick, NJ, USA). Rats were
maintained on the diet for 16 weeks and body weights were measured throughout
treatment. Following dietary treatment, animals were maintained on the diet as they
underwent behavioral, neurochemical studies as well as post diet biochemical studies. At
sacrifice, trunk blood was collected and brains were harvested.
2.3.2

Behavioral Testing
In mice, following the CMS behavioral paradigm, animals underwent behavioral

testing for anxiety and depressive-like phenotypes. Elevated zero maze (EZM) was
conducted as previously described (Tucker and McCabe, 2017). Each mouse was placed
into the closed arm of the apparatus (Maze Engineers, Boston, MA, USA) and allowed to
explore for 5 min. Time spent in the closed arm was measured as an indicator of anxietylike behavior. Tail suspension test (TST) was completed as previously described (Sanna
et al., 2017). attached via tape to the rod and a small plastic, flexible tube was placed on
the tail to limit climbing behavior within the apparatus (Maze Engineers, Boston, MA,
USA) for the duration of the 6 min test. Percent immobility was measured in the first two
min (pretest) and the remaining 4 min (test) as an indicator of depressive-like behavior.
In rats, A sucrose preference was performed as described in Grillo et al. (Grillo et
al., 2011). On pretest and test days, water was removed at 12 PM, animals were given
water and 1% sucrose in water bottles at 7 PM. Bottles were weighed at 1, 2, 3, and 12
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hrs. following administration. Sucrose preference was determined as the amount of
sucrose water consumed over the total fluid (water and sucrose water) consumed. There
was no significant difference in water consumption between treatment groups.
2.3.3

Surgical Procedures
In mice, surgery was performed following an i.p. injection of 25% w/v urethane

(7 μL/g of body weight) (Sigma–Aldrich Co., St. Louis, MO, USA, dissolved in 0.9%
NaCl solution, Hospira, Lake Forest, IL, USA) to maintain and induce anesthesia. Mouse
body temperature was maintained using a heating pad (Braintree Scientific, Braintree,
MA, USA). Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) was
performed, and all coordinates were taken in reference to bregma. A Nafion TM-modified
CFM was lowered into the CA2 region of the hippocampus (5HT: AP: -2.91, ML: +3.35,
DV: -2.5 to -3.0) (Franklin, 2013), into the medial prefrontal cortex (mPFC) (5HT: AP:
+1.7, ML: -0.2, DV: -2.2 to -2.9), or into the posterior hypothalamus (HA: AP: -2.45,
ML: +0.5, DV: -5.45 to -5.55) (Franklin, 2013) and adjusted in the dorsal/ventral plane
until a serotonin/histamine signal was observed. A stimulating electrode (insulated
stainless steel, diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was
placed into the medial forebrain bundle (MFB; (5HT: AP: -1.58, ML: +1.00, DV: -4.8) or
(HA: AP: -1.07, ML: +1.10, DV: -5.0)) (Franklin, 2013) and a pseudo Ag/AgCl reference
electrode, created by electroplating chloride (30 s in 0.1 M HCl at 5 V) onto a silver wire,
was placed into the contralateral hemisphere.
In rats, surgeries were performed in the same manor, however, the rats were
anesthetized using isoflurane (Piramal Healthcare, Mumbai, IND). During rat surgeries,
all coordinates were determined in reference to bregma and a Nafion-modified carbon
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fiber microelectrode was placed into the hippocampus/CA2 (AP -5.5 mm, ML +5.0 mm,
DV -4.0 mm) (Paxinos and Watson, 2006). A stainless-steel stimulating electrode
(diameter 0.2 mm, Plastics One, Roanoke, VA, USA) was placed into the MFB (AP -2.8
mm, ML +1.7 mm, DV -8.0 mm) (Paxinos and Watson, 2006). Additionally, a Ag/AgCl
reference electrode was placed in the contralateral hemisphere.
2.4

Voltammetric Data Collection
FSCV and FSCAV were performed using a Dagan potentiostat (Dagan

Corporation, Minneapolis, NM, USA), WCCV 3.06 software (Knowmad Technologies
LLC, Tucson, AZ, USA), either a Dagan or Pine Research headstage (Pine Research
Instrumentation, Durham, NC, USA), and National Instruments DAQ cards NI-6341 and
NI-6221 (NI, Austin, TX, USA). For FSCV collection, the “Jackson” serotonin waveform
(Jackson et al., 1995) was applied to the electrode at a scan rate of 1000 V s -1and at a
frequency of 10 Hz or the histamine waveform, was applied at a scan rate of 600 V s -1
and at a frequency of 10 Hz (Samaranayake et al., 2015). To evoke serotonin or histamine
release, a biphasic stimulation was applied through a linear constant current stimulus
isolator (NL800A Neurolog, Medical Systems Corp, Great Neck, NY, USA) with the
following parameters: 60 Hz, 360 μA each, 2 ms in width, and 2 s in length. Four control
files of serotonin or histamine were collected 10 min apart for each animal prior to
injection of pharmacological agents. Following voltammetry data collection, a high
voltage was applied to the CFM to lesion the tissue around the electrode which enables
electrode placement verification in post-mortem histological analyses.
For basal experiments, control evoked files were collected followed by the
methodology being switched to FSCAV. For FSCAV collection, the serotonin waveform
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was applied at 100 Hz for 2 s, followed by a period of controlled adsorption where the
potential was held at 0.2 V for 10 s, lastly the serotonin waveform was reapplied at 100
Hz, as described in Abdalla et al. (2017). Thirty files (at one file per minute) were
collected as control files. Following control files, an i.p. injection of saline was
administered and 30 more files of FSCAV were collected. Animals were then
administered pharmaceutical agents like ESCIT (10 mg kg-1) i.p. and 60 files post-ESCIT
were collected. The system was then switched back to traditional FSCV and four postbasal stimulation files were collected. Electrodes were then removed and underwent a
post calibration in which 10 files were collected with the electrode in solutions of 10, 25,
50, and 100 nM solutions of serotonin.
For stimulation during basal experiments, the stimulation was completed as
previously described (at 0, 5, 10, 20, 30 min). Ten control FSCAV file were collected (10
min) and FSCAV data collection was maintained throughout the stimulation paradigm
(30 min) and additional post stimulation files (60 min) for a total of 100 min of FSCAV
data collection.
2.5

Voltammetric Data Analysis and Statistics
Data were analyzed using WCCV software digital filtration (zero phase,

Butterworth, 5 kHz low-pass) and smoothing. For FSCV analysis, the cyclic
voltammogram (CV) was used for both histamine and serotonin and the current vs. time
(IT) was extracted to resolve release and reuptake of both neurotransmitters. A previously
established calibration factor (49.5 ± 10.2 nA/μM) for serotonin analysis and 2.825
µM/nA for histamine and 11 nM/nA for serotonin were used to convert current to
concentration (Samaranayake et al., 2015; Samaranayake et al., 2016).
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For FSCV data, four IT curves were averaged for each animal to establish a
control. The average for each individual animal was then combined with the other
animals in the group to determine an overall group average. The standard error of the
mean (SEM) was calculated using the average IT for each animal (n = # animals). To
determine significance between two points, a two-tailed student’s t-test was utilized (p <
0.05) and is denoted throughout the text as an asterisk (*).
For FSCAV analysis, the third CV after the reapplication of the waveform was
selected for quantification, and the peak occurring approximately between 0.4 and 0.85 V
was integrated to determine the charge value (pC). Post calibrations of each electrode,
plotting charge (pC) vs. [serotonin] (nM), were used to determine basal concentration.
Animals were only excluded if signals were determined to be outliers via the
Grubbs test for outliers or if they did not survive the experimental paradigm. To
determine the t1/2, a code was custom written in excel to fit the reuptake component of the
curve and calculate the time taken to reach half of the maximum amplitude. The number
of files with a concentration of less than zero was used to quantify the “dip” below
baseline, associated with autoreceptors, which will be covered in more detail below.
Determination of the percent reuptake change following ESCIT is explained in Section
“Modeling.”
Sample size = 2 SD2 (Zα⁄2 + Z β )2 /d2
The pooled standard deviation from the sample data was 0.83 and Cohen’s d was
calculated as 1.76. The Zα/2 term was 1.96 (from Z table) as a type 1 error of 5% and the
Zβ was 0.842 (from Z table) at 80% power. This power analysis resulted in a n = 3.5. The
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sample size corrected for exclusion was calculated using n = 3.5 and a percent loss of
animals as 8%, showing that about 3.8 animals were required.
2.6

Modeling
A previously presented mathematical model was used to model the average male

and female evoked responses:
𝑑[𝑆(𝑡)]
𝑉𝑚𝑎𝑥1 [𝑆(𝑡)]
𝑉𝑚𝑎𝑥2 [𝑆(𝑡)]
= 𝑅(𝑡)(1 − 𝐴(𝑡)) − α
−β
𝑑𝑡
𝑘𝑚1 + [𝑆(𝑡)]
𝑘𝑚2 + [𝑆(𝑡)]
S(t) is the concentration of serotonin in the extracellular space, R(t) is the release
rate of the serotonin neurons in the hippocampus near the electrode that rises briefly after
stimulation and then returns to baseline, and A(t) represents the strength of the
autoreceptor effect caused by rising serotonin in the extracellular space [the higher A(t)
the more serotonin release is inhibited] (Wood et al., 2014). The first negative term
represents reuptake resulting from Uptake 1 transporters, the serotonin transporters
(SERTs), with Vmax1 = 19.25 nM s-1 and Km1 = 5 nM. The second term represents
reuptake via Uptake 2 transporters [dopamine transporters (DATs), norepinephrine
transporters (NETs), and organic cation transporters (OCTs)] with Vmax2 = 780 nM s-1 and
Km2 = 170 nM. We modeled and discussed Uptake 1 and Uptake 2 in detail previously
(Wood et al., 2014). Briefly, Uptake 1 is high affinity but low efficiency serotonin
transport (Shaskan and Snyder, 1970) while Uptake 2 is low affinity, high efficiency
serotonin transport (Daws et al., 2013; Horton et al., 2013). Thus, at serotonin
concentrations well above the basal level, Uptake 2 is primarily responsible for serotonin
removal from the extracellular space, but low concentrations, closer to the steady state,
Uptake 2 has little effect on reuptake of serotonin. For the purpose of our simulations, we
assume the basal steady state is 60 nM, roughly the mean of measured basal levels, and
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the parameter beta decreases from 0.05 above 82 nM linearly to zero at 62 nM, reflecting
the properties of Uptake 2. In some simulations, the concentration cutoffs 82 and 62 nM
are slightly varied to fit the experimental data. In all our simulations, α = 1. We believe
that stimulation of the MFB causes antidromic spikes that stimulate the dorsal raphe
nucleus (RN). The increased firing of RN neurons increases the release rate, R(t), in the
hippocampus. Before stimulation, we assume that R(t) is a constant, R0, chosen so that the
basal steady state is 60 nM. After stimulation, R(t) rises linearly for 1 s followed by decay
back to R0 linearly over 2 s. This value can be varied to reflect the different release rates
produced by slight differences in the stimulation of the MFB. The parameter r scales how
high above R0 the release rate goes, with r= 1 indicating an increase of release rate of 40
nM s-1. We previously showed that the autoreceptor effects are long-lasting (up to 30 s)
and continue after both R(t) and S(t) have returned to baseline (Wood et al., 2014). This
longer lasting autoreceptor effect drives the serotonin concentration below baseline after
most stimulations.
The model was further used to calculate estimates of the percentage decrease of
Vmax2 caused by different doses of ESCIT in male mice and female mice (Figure 4).
These calculations were carried out assuming that most of the initial decrease of
serotonin in the extracellular space is caused by the Uptake 2 transporters. This
assumption is supported by our previous work (Wood et al., 2014). The experimental data
give us the evoked serotonin response before ESCIT (control curve) and the evoked
serotonin response 30 min following the administration of ESCIT (dose curve). As the
Km2 of Uptake 2 is known, the control signal was used to calculate the value of the
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effective Vmax2 for the control signal. The process was repeated for the ESCIT signal to
calculate the effective Vmax2 for the ESCIT signal.
2.7

Biochemical Analyses
Biochemical assays, enzyme-linked immunosorbent assays (ELISAs), and

bioplexes were used to analyze biological molecules such as triglycerides (Pointe
Scientific, Inc., Canton, MI, USA), leptin (MilliporeSigma, Burlington, MA, USA),
cytokines (Bio-Rad Laboratories, Hercules, CA, USA) in plasma and homogenized brain
tissue.
2.8

Immunohistochemistry
Immunohistochemistry was performed as described in our previous studies

(Reagan et al., 2001; Grillo et al., 2005; Reznikov et al., 2008). For immunofluorescence
studies, rat brain sections were washed with phosphate buffer solution and then incubated
with primary antisera raised against the presynaptic protein synaptophysin (1:1000
dilution; Santa Cruz Biotechnology Inc., Dallas, TX, USA) and the postsynaptic protein
PSD-95 (1:1000 dilution; Upstate Biotechnology, Lake Placid, NY, USA). Following an
overnight incubation at 4ºC, sections were washed in phosphate buffer solution and then
incubated with secondary antisera conjugated with Alexa 488-labeled anti-rabbit IgGs
(1:200, Molecular Probes, Eugene, OR, USA) and Alexa 568-labeled anti-mouse IgGs
(1:200, Molecular Probes, Eugene, OR, USA) for 3-4 hrs at room temperature. Following
incubation with secondary antisera, sections were rinsed in phosphate buffer solution,
mounted on glass slides and coverslipped with Aquamount (Polysciences, Inc.,
Warrington, PA, USA). Sections were examined with a Zeiss LSM510 confocal laser
scanning microscope.
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2.9

Cell Culture
Human iPSCs were differentiated into serotonergic neurons as described

previously (Lu et al., 2016). Additional SERT staining was also completed as previously
described (Matthäus et al., 2016). FSCV measurements were completed using coverslips
of Tryptophan (TRP+) containing serotonergic neuronal cell clusters and submerging
them in room-temperature solution of 2.5 mM glucose in HEPES buffer in a 35 mm low
wall imaging dish (ibidi GmbH, Martinsried, GER). A faraday cage (aluminum foil
connected to ground) was placed on a Leica DM IL inverted microscope. CFM were
adjusted to 100 µm in length and micromanipulators (QUAD, Sutter Instruments, Navato,
CA, USA) were used to position the CFM and the stimulation electrodes. Stimulation
was adjusted to 250 µA for in vitro FSCV.
2.10

Statistics
All data are presented as the average with the standard error of the mean (SEM).

Significance was determined between two or more points using a 2-tailed student’s t-test
or an ANOVA and significance was defined and denoted as * = p < 0.05 and # = p <
0.01.
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CHAPTER 3
IN VIVO SEROTONIN DYNAMICS IN MALE AND FEMALE MICE:
DETERMINING EFFECTS OF ACUTE ESCITALOPRAM USING FASTSCAN CYCLIC VOLTAMMETRY3

3
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3.1

Abstract
Depression is a highly prevalent psychiatric disorder, impacting females at a rate

roughly twice that of males. This disparity has become the focus of many studies which
are working to determine if there are environmental or biological underpinnings to
depression pathology. The biology of depression is not well understood, but experts agree
that a key neurotransmitter of interest is serotonin. Most research on basic serotonin
neurochemistry, by us and others, has predominantly focused on male models. Thus, it is
now critical to include female models to decipher possible fundamental differences
between the sexes that may underlie this disorder. In this work, we seek to determine any
such differences using fast-scan cyclic voltammetry (FSCV) and fast-scan controlled
adsorption voltammetry (FSCAV). These techniques allow us to probe the serotonergic
system via measurement of evoked and ambient serotonin at carbon fiber microelectrodes
(CFMs). Our data reveal no statistical differences, in the hippocampus, in female
serotonin chemistry during the different stages of the estrous cycle compared to the mean
female response. Furthermore, no difference was observed in evoked serotonin release
and reuptake, nor ambient extracellular serotonin levels between male and female mice.
We applied a previously developed mathematical model that fits our serotonin signals as
a function of several synaptic processes that control the extracellular levels of this
transmitter. We used the model to study potential system differences between males and
females. One hypothesis brought fourth, that female mice exhibit tighter autoreceptor
control of serotonin, is validated via literature and methiothepin challenge. We postulate
that this tight regulation may act as a control mechanism against changes in the serotonin
signal mediated by estrogen spikes. Importantly, this safety mechanism has no
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consequence for acutely administered escitalopram’s (ESCIT’s) ability to increase
extracellular serotonin between the sexes. This work demonstrates little fundamental
differences in in vivo hippocampal serotonin between the sexes, bar control mechanisms
in female mice that can be observed under extraneous circumstances. We thus highlight
the

importance

of

considering

sex

as

a

biological

factor

in

determining

pharmacodynamics for personalized medical treatments that involve targeting serotonin
receptors.
3.2

Introduction
Clinical depression is more than twice as prevalent in adult females than males

(Weissman and Klerman, 1977; Kessler et al., 1993; Hankin et al., 1998; Cyranowski et
al., 2000; Piccinelli and Wilkinson, 2000; Grigoriadis and Robinson, 2007) and
antidepressants exert varying degrees of efficacy by sex (Frackiewicz et al., 2000;
Sramek and Cutler, 2011). Interestingly, most studies show this sex-dependent increased
risk of depression only emerges post-puberty (Anderson et al., 1987; McGee et al., 1992;
Nolen-Hoeksema and Girgus, 1994). This disparity in adult depression rates has been
explained via environmentally induced (i.e., societal stress) or innate (fundamental
biology) phenomena (Sullivan et al., 2000; Eley et al., 2004). The idea that there are
inherent biological underpinnings to depression is well-debated and hypotheses that have
been brought forth over the years have not had unanimous acceptance (Asberg et al.,
1976b; Asberg et al., 1976a; Owens and Nemeroff, 1994). Historically, preclinical and
basic research has not encompassed both sexes equally, with a strong bias toward male
models. This approach was formed under the preconception that the estrous cycle
confounds experimental data, however, as stated in NOT-OD-15-102 in 2015, “An
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overreliance on male animals and cells may obscure understanding of key sex influences
on health processes and outcomes” (National Institutes of Health, 2015). Henceforth,
there is a strong emphasis on including male and female mice in all basic and preclinical
studies.
We are in a good position to study intrinsic neurochemical differences that may
drive depression and antidepressant actions in male and female animal models since we
can monitor sub-second changes in serotonin in real time, in vivo. Serotonin is a wellestablished transmitter of interest to depression and antidepressant activity in both sexes
(Piccinelli and Wilkinson, 2000; Sramek and Cutler, 2011). We monitor serotonin
dynamics in vivo using voltammetric techniques, fast-scan cyclic voltammetry (FSCV)
and

fast-scan

controlled

adsorption

voltammetry

(FSCAV)

at

carbon

fiber

microelectrodes (CFMs). FSCV enables the in vivo monitoring of the release and
reuptake of serotonin on a sub-second timescale (Hashemi et al., 2009; Wood and
Hashemi, 2013; Wood et al., 2014) and FSCAV quantifies ambient serotonin
concentrations on the order of tens of seconds (Abdalla et al., 2017).
In this article, we study the in vivo serotonin chemistry in the CA2 region of the
hippocampus of male and female mice. We chose to start this study with the
hippocampus because of this brain region’s heavy association with depression and
antidepressant actions. For example, decreased hippocampal volume is found in human
and animal models of depression (Magarinos et al., 1996; Sheline et al., 1996; Bremner et
al., 2000; Videbech and Ravnkilde, 2004). Furthermore, selective serotonin reuptake
inhibitors (SSRIs) are shown to change hippocampal architecture via neurogenesis (Czeh
et al., 2001; Malberg and Duman, 2003; Jayatissa et al., 2006). In our cohort of female
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mice, statistical differences are not found in serotonin signals between the overall female
mean and the different stages of the estrous cycle. Importantly, evoked serotonin release,
reuptake, and ambient serotonin in 23 female (all cycle stages) and 23 male mice are not
statistically different. Potential functional differences are investigated by mathematically
modeling the averaged male and female responses as a measure of several synaptic
processes that regulate extracellular serotonin. Specifically, the evoked signal in male
mice is postulated to have higher input and the signal in female mice is hypothesized to
undergo tighter autoreceptor control. We provide validation of the model’s autoreceptor
hypothesis in female mice via administration of methiothepin, a non-selective serotonin
receptor antagonist with high affinity for the serotonin autoreceptors. We put forth that
this stronger autoreceptor control may act as a safety mechanism against serotoninmediating estrogen spikes. To understand whether these autoreceptor effects are
consequential for SSRI response, we compare administration of acute doses of the SSRI,
escitalopram (ESCIT) to male and female cohorts of mice, some of which are pretreated
with methiothepin. The percent change in serotonin reuptake is less dramatic across all
doses of ESCIT in females but this effect is independent of autoreceptor antagonism.
In summary, serotonin chemistry, in the hippocampus, during the different stages
of the estrous cycle is not different from the mean in female mice and the control evoked
release, reuptake, and ambient serotonin are not statistically different between the sexes.
On the microanalysis level, differences in serotonin regulation between male and female
mice may lie, in part, in autoreceptor regulation. This finding is especially useful when
considering pharmacodynamics for personalized medical treatments that involve
serotonin receptors.
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3.3

Results

3.3.1

Serotonin During the Different Stages of the Estrous Cycle
Evoked and basal serotonin was measured during each stage of the estrous cycle

in the CA2 region of the hippocampus in female mice (images verifying stage of cycle
are found in Figure A.2). The basal serotonin concentrations were added to the
respective animals’ evoked response and are displayed in the colored traces in Figure 3.1
for each stage of the estrous cycle (n = 3–4). The gray traces in Figure 3.1 are the
averaged female responses (blinded for stage of estrous cycle, n = 10). When comparing
the data from each stage of the cycle to the average, we found no significant differences
in evoked release amplitude and t1/2 of serotonin clearance (table in Figure 3.1).

Figure 3.1: Serotonin across the female estrous cycle. Serotonin signals, incorporating
respective basal levels, from each of the four estrous cycles in female mice are shown.
The average from female mice in the estrus (red, n = 4), metestrus (yellow, n = 4),
diestrus (green, n = 3), and proestrus (purple, n = 3) stages are shown. A table showing
the average amplitude and t1/2 for each stage of the female mouse cycle along with the pvalue resulting from a two-tailed t-test is seen below. Significance was defined as p <
0.05.
3.3.2

Evoked and Basal Serotonin in Male and Female Mice
Evoked serotonin was measured in male and female mice (regardless estrous

cycle stage). Results are shown in Figure 3.2 where Figure 3.2A shows the average
serotonin concentration ([serotonin]) vs. time traces in male and female mice and Figure
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3.2B shows the raw data of each individual making up the averages shown in Figure
3.2A. The results of FSCAV experiments in male and female mice are seen in Figure
3.2C. The values for the maximum amplitude of serotonin release, the t1/2 of serotonin
clearance, and the average ambient [serotonin] are in the table in Figure 3.2C (middle).
These results demonstrate no significant difference in the evoked release amplitude (35.0
± 3.3 nM in males and 32.2 ± 4.3 nM in females, p = 0.61, two-tailed student’s t-test), t1/2
of serotonin clearance (2.1 ± 0.2 s in males and 2.1 ± 0.2 s in females and p = 0.93, twotailed student’s t-test), or average ambient serotonin levels [62.5 ± 1.8 nM in males and
60.4 ± 1.8 nM in females (p = 0.43, two-tailed student’s t-test)]. To determine if these
results are specific to the hippocampus, we explored an additional brain region, the
mPFC (Supplementary Figure S3). No statistical difference was found in this region
between the male and female mice.
3.3.3

Mathematically Modeling Male and Female Serotonin Signals
Figure 3.3 shows the results of fitting the averaged male and female serotonin

responses with a model that we previously developed that captures experimental data in
the context of the synaptic mechanisms that control extracellular serotonin. In these
animals that we reported evoked release, ambient serotonin data were not available. Thus,
to give basis to the model, an average concentration from a subset of mice in this work
(60 nM) was added, arbitrarily, to each signal. The amplitude of the signal in male mice
was higher than in the female mice, which was modeled via a larger input term to the
terminal (r = 0.54 in males, r = 0.43 in females). Additionally, there was a larger dip
below baseline after stimulation in female mice, which was modeled via a larger value
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for the autoreceptor term in the model. We described this autoreceptor phenomenon at
length previously (Wood et al., 2014).

Figure 3.2: Evoked hippocampal serotonin in male and female mice. (A) The average
evoked serotonin for male mice (blue, n = 23) and female mice (red, n = 23) with SEM
shown in a lighter shade around each. Serotonin was evoked via a short stimulation
(yellow bar). (B) The average basal serotonin concentration found in male (n = 17, shown
in blue) and female (red, n = 18) animals is shown, along with the SEM of each. (C)The
table details male and female average maximum evoked [serotonin] amplitude, the
average t1/2 of serotonin clearance and the average basal [serotonin]. (D) The raw data for
each individual mouse used to generate the average evoked serotonin signal are shown in
varying shades of blue (male) and red (female). Significance was defined as p < 0.05.
3.3.4

Serotonin Response to ESCIT
An acute ESCIT dose, was administered via i.p. injection, to male and female

mice, separately at 3, 10, and 30 mg kg-1 and the evoked and basal serotonin responses
were monitored in separate cohorts of mice per dose. The evoked responses, seen in
Figure 3.4, are shown for each dose along with the percent change in reuptake. At every
dose, the female mice had a lower percent change in reuptake compared to the males.
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Figure 3.3: Modeling of evoked serotonin in male and female mice. The average
experimental serotonin signal from male (A) and female (B) mice is shown plotted with
the modeled serotonin signal. An average basal value of 60 nM has been incorporated
into the male and female responses.
The basal, steady-state serotonin concentration response to ESCIT is shown
in Figure 3.5 in male and female mice. Control files were collected for 30 min, after
saline injection, files were taken for 30 min, finally ESCIT was administered and files
were taken for an additional hour. Serotonin was not altered by saline, while roughly 10
min after ESCIT, the signal rose ∼43–46%. This represented a significant change in
serotonin in both sexes (p < 0.01, two-tailed student’s t-test) but no significant difference
between the two sexes (p = 0.96, two-tailed student’s t-test). Likewise, the basal
serotonin concentrations before and after ESCIT were not significantly different between
males and females (p = 0.244 and p = 0.220, respectively, two-tailed student’s t-test).
3.4

Discussion

3.4.1

Control Serotonin Chemistry Is Not Significantly Different Between the

Sexes in the Hippocampus
The possible inherent biological underpinnings of depression are not well
understood and hypotheses that have been brought forth over the years have not had
unanimous recognition. It is well established that alterations in serotonin chemistry likely
underlie the behavioral phenotypes of depression (Asberg et al., 1976b; Asberg et al.,
63

Figure 3.4: ESCIT dose response in male and female
mice. The male (blue) and female (red) evoked serotonin
signals are shown (n = 4 for each). A lighter color is shown
to indicate control release and a darker shade is used to
denote response 30 min following i.p. ESCIT administration
(3, 10, and 30 mg kg-1). The table lists percent decrease of
reuptake in males and females at the three doses.
1976a; Owens and Nemeroff, 1994; Stockmeier, 2003). We are in a good position to
investigate the chemistry of the serotonin system from a fundamental perspective. Our
techniques, FSCV and FSCAV, allow us to probe the essence of synaptic release and
reuptake of serotonin via the many parallel systems that regulate this transmitters’
extracellular concentration.
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There is a belief that neurochemistry in female rodents is intrinsically more
variable due to the estrous cycle (Beery and Zucker, 2011). Accordingly, the majority of

Figure 3.5: Basal serotonin in male and female mice following ESCIT. The male
(blue, n = 5) and female (red, n = 5) basal serotonin levels were collected for 30 min. A
saline injection (marked by a yellow bar) preceded another 30 min of basal serotonin data
was collected. At the gray bar, escitalopram (ESCIT, 10 mg kg -1) was administered and
60 min of basal serotonin data was collection. SEM is shown as a lighter bar behind.
studies on serotonin’s role in depression and antidepressant effects (including our own)
have so far only been in male mice (Borsini and Meli, 1988; Stahl, 1998; Wood and
Hashemi, 2013; Abdalla et al., 2017). Here, we perform the first FSCV serotonin
measurements in female mice and investigate whether the different stages of the estrous
cycle alter the characteristics of serotonin neurochemistry. The estrous cycle in rodents is
approximately 4–5 days long and is divided into four stages: proestrus, estrus, metestrus,
and diestrus. These stages can be determined through looking at the difference in cell
types in a vaginal smear under a standard light microscope and correlating those
differences to the stage of estrous cycle (Caligioni, 2009; Byers et al., 2012)
(Supplementary Figure S2). The phase of the estrous cycle for each female mouse was
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recorded and the responses of the mice in each respective cycle were averaged. Figure
3.1 shows that none of the averaged responses between the cycles differ statistically from
the mean of 10 females blinded for stage of cycle. Estrogen is thought to modulate
serotonin (Biegon et al., 1980; Rubinow et al., 1998), although it is unclear to which
extent this phenomenon extends during the different stages of the cycle (Gundlah et al.,
1998; Maswood et al., 1999; Bethea et al., 2002). Overall, our data do not have enough
significance to support this notion in the hippocampus. Additional data from male and
female mice in the mPFC (Supplementary Figure S3) also show no significant differences
between the sexes. An important caveat here is that, while the hippocampus and mPFC
are brain regions heavily implicated in depression and antidepressant actions (Goldapple
et al., 2004; Kodama et al., 2004; Drevets et al., 2008), our study has not included other
brain regions thought to be important in the pathology depression, which may show
differences. An additional point of note is the age range of animals used here since there
is evidence that depression rates vary with age (Anderson et al., 1987; McGee et al.,
1992; Hankin et al., 1998; Piccinelli and Wilkinson, 2000). We utilized a broad age range
(6–12 weeks) to maximize potential observable differences. In Supplementary Figure
A.1, we found no statistical differences between young adult (6–8 week old) and adult
(9–12 week old) mice.
Scientists have found a variety of sex differences in rodents related to serotonin
including: metabolism (Curzon and Bridges, 1970; Rosecrans, 1970; Kennett et al.,
1986), synthesis (Nishizawa et al., 1997), receptor binding (Fischette et al., 1983; Arango
et al., 1995; Parsey et al., 2002; Jovanovic et al., 2008), transporter functions (McQueen
et al., 1997; Jovanovic et al., 2008), extracellular levels (Gundlah et al., 1998), and many
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other processes (Biegon et al., 1980; Rubinow et al., 1998; Dominguez et al., 2003).
However, parallel studies have found little to no differences in other aspects of the
serotonin system (Rosecrans, 1970; Kunimura et al., 2015). This incongruity makes it
very difficult to ascertain whether the serotonin system plays a fundamental role in the
disparity of depression between male and females.
In Figure 3.2A, we see that evoked release and reuptake of serotonin is
remarkably reproducible in male vs. female mice. A point of note is the high precision of
these experimental data. These data (Figure 3.2D) are essentially raw data (two analysis
steps include smoothing the data and conversion of current to concentration). These data
are highly reproducible, in contrast to other chemical data that often needs to be
normalized and shown as a % change from baseline (Kaminska et al., 2018; Wojcieszak
et al., 2018). Also, compared to dopamine voltammetry studies, where significant
heterogeneity manifests as “hotspots” of dopamine activity (May and Wightman, 1989;
Wightman et al., 2007), these serotonin data are much more uniform.
In Figure 3.2B, in the interest of scientific transparency, we purposefully show all
of our raw data that were used to generate the average curves illustrated in the bottom
panel. The SEM of the maximum amplitude of the average female curve is 4.3 nM. This
small error is in accordance with our long-standing hypothesis that the serotonin system
is a profoundly regulated one (Hashemi et al., 2009; Wood et al., 2014). Standard
statistics showed no difference in the amplitude or t 1/2 and of evoked release nor in basal
[serotonin] (Figure 3.2). These statistical findings emphasize both the high
reproducibility of our data and the tightly controlled in vivo serotonin system. To
summarize these data: there are no statistical differences between the stages of the cycle
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and the mean in females. Critically, the averaged responses between male and female
mice are not different in the CA2 region of the hippocampus.
3.4.2

Modeling Serotonin Signals Reveals Potential Regulation Differences
We previously developed a model that deconstructs the chemical signal as a

function of the many synaptic processes that control extracellular serotonin. Thus,
modeling the experimental data can provide specific information about the components
of system (Wood et al., 2014). As a starting point, we fit the averaged male and averaged
female experimental data; the model hypothesized two differences between the male and
female evoked response. First, the evoked response in males necessitated a larger model
input term to the terminal. Second, a stronger autoreceptor term was necessary to model
the female data. This finding is insightful but requires further verification since the model
was based on the average, and not individual data. To further verify these notions, we
hypothesized potential biochemical processes that underlie the findings.
Larger Model Input Term to the Terminal in Males
To model the experimental data, a larger input term was required in male mice to
fit the larger amplitude of evoked serotonin release. We hypothesize three biochemical
reasons for this larger input. First, a higher amplitude response could be the result of
more axons. However, in most investigations, there have not been significant differences
found in the number of serotonin axons between male and female mice (Jitsuki et al.,
2009; Kunimura et al., 2015; Rajkowska et al., 2017). Second, we postulate that axons in
male mice have a lower stimulation threshold than in female mice. The literature has
come to no consensus on this front (Yang et al., 2015; Strupp-Levitsky et al., 2016).
Third, we put forth that more vesicular serotonin is released in response to stimulation in
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male mice. This could be a result of a variety of changes within the synapse ranging from
vesicle number, Ca2+ dependent vesicular release, amount of serotonin released with each
vesicle fusion, or catabolism of released serotonin; again, these possibilities remain
inconclusive based on current literature (Mermelstein et al., 1996; Nishizawa et al., 1997;
Rehavi et al., 1998).
Larger Model Autoreceptor Term in Females
Previously, we showed that the dip below baseline after stimulation was a fall in
serotonin levels (Wood et al., 2014). We modeled and pharmacologically verified that
this decrease in ambient serotonin level was due to prolonged autoreceptor control. In
these data, the model captured a larger dip below baseline in females by necessitating a
larger autoreceptor term. We postulate that this is a function of a higher density of, or
higher functionality of autoreceptors in females. A significant amount of current research
suggests sex may affect quantity and function of autoreceptors (Jones and Lucki, 2005;
Goswami et al., 2010; Goel et al., 2014). Jones and Lucki (2005), in particular,
determined that 5HT1B autoreceptor knockout mice exhibited a sex-dependent increase
in baseline hippocampal serotonin present only in females. Goswami et al. (2010) found
increased levels of 5HT1D autoreceptor mRNA in serotonin neurons in the dorsal raphe
of females with major depressive disorder compared to control females, a trend that did
not persist in male subjects.
The literature does not enable verification of the model’s two hypotheses, yet it is
important to verify whether these fundamental differences in serotonin chemistry exist in
the context of depression and/or antidepressant efficacy in males vs. females. As a
pharmacological means to verify these hypotheses, we study acute methiothepin (non-
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selective serotonin receptor antagonist, with high affinity for the autoreceptors) and
ESCIT administration.
3.4.3

Escitalopram Induced Differences in Serotonin Uptake but Not Basal

Concentrations Between Sexes
With the increasing global rate of depression, the issue of antidepressant efficacy
is brought to the forefront. SSRIs have been shown to have different effects in male and
female patients in clinical trials (Kornstein et al., 2000; Khan et al., 2005). In rodents,
SSRIs have differential effects by sex. For example, male and female rodents respond
differently in the forced swim test (FST) (Cryan et al., 2002; Drossopoulou et al., 2004;
Petit-Demouliere et al., 2005; Bogdanova et al., 2013). The FST is a behavioral test;
among other uses, it has been used to screen for antidepressant efficacy after acute i.p.
SSRI injections in naive animals (Borsini and Meli, 1988; Willner, 1990).
In the context of antidepressant effects in male vs. female mice, we sought to test
the two hypotheses brought forth by the model by adhering to the traditional SSRI
screening procedure (acute SSRI i.p. injection). The first hypothesis was that there is a
higher input to the serotonin terminals in male mice resulting in higher amplitude of
evoked release. For the hypothesis to hold, this amplitude difference is expected to persist
after SSRI. We used three different doses of ESCIT and presented averaged control
evoked responses (n = 4 animals) and the averaged responses 30 min after SSRI
administration. ESCIT administration slowed the reuptake of serotonin, as predicted by
the mechanism of action of this agent. Notably, following ESCIT, there was a systematic
increase in the signal amplitude; however, there was no consistency in amplitude change
between the doses in the two sexes. Specifically, at 30 mg kg-1, the female ESCIT
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response amplitude is higher than that of the males. This finding nullifies the model’s
first hypothesis, since the higher amplitude in males did not persist across all doses.
In addressing the second hypothesis brought forth by our model, that there is
stronger autoreceptor regulation in females, we found that acute ESCIT was less effective
at decreasing the rate of serotonin reuptake at all doses in female mice. We propose that
this phenomenon could be due to increased functionality of the serotonin autoreceptors, a
notion supported in the literature (Jones and Lucki, 2005; Goswami et al., 2010; Goel et
al., 2014). Increased autoreceptor activity could counteract SERT-mediated effects of the
SSRI, especially since 5HT1B autoreceptors are G-protein coupled to the SERTs and
have previously been found to mediate serotonin reuptake (Montanez et al., 2014). A
potential rationale for increased autoreceptor control in female mice is the modulation of
serotonin by estrogen in the brain (Biegon et al., 1980; Lu et al., 1999; Bethea et al.,
2002; Abraham et al., 2003; Sheng et al., 2004; Cornil et al., 2006; Barth et al., 2015;
Kunimura et al., 2015), a complex relationship previously examined in in-depth reviews
(Rubinow et al., 1998; Borrow and Cameron, 2014). Estrogen is thought to modulate
serotonin in both male and female mice on both a slower, ambient level as well as rapid,
transient effects which can alter intracellular signaling (Abraham et al., 2003; Cornil et
al., 2006). The rapid changes in estrogen are more commonly associated with female
models (Hansel and Convey, 1983). To protect against these “spikes” in estrogen, we
propose the stronger activity of autoreceptors in female mice serve as a control
mechanism. High levels of extracellular serotonin are neurotoxic (Boyer and Shannon,
2005). In accordance with this, other researchers have found increased density of 5HT1
autoreceptors and a higher rate of serotonin turnover in female vs. male mice, mediated
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by estrogen (Biegon et al., 1980; Carlsson et al., 1985). To test this notion, we pretreated
male and female mice with methiothepine (0.1 mg kg-1) before ESCIT administration
(Figures 3.6A,B). We were limited to using this small methiothepin dose because when
administered with SSRI, receptor antagonists induce the fatal serotonin syndrome
pathology. Statistically, we found that the “dip” below baseline, that we previously
attributed to serotonin autoreceptors (Wood et al., 2014), is diminished in both sexes, but
to a larger extent in female mice (191 ± 13 data points in the controls to 64.8 ± 45 files
after methiothepin treatment, p = 0.048). This could point toward the fact that the female
serotonin signal is under greater autoreceptor control since the same dose creates a larger
effect (less of a correction is needed to prevent the “dip” in males). While these data are
good evidence for stronger autoreceptor regulation in females, we find no effects of
methiothepin pretreatment on the t1/2 of the ESCIT response (Figures 3.6C,D where
responses are normalized from animals with and without methiothepin treatment). We
thus reject the notion that autoreceptors are responsible for the lesser effect of ESCIT on
the reuptake curve of serotonin in female mice. Other hypotheses that may account for
this sex specific response to acute SSRI include metabolic effects (Curzon and Bridges,
1970; Rosecrans, 1970; Kennett et al., 1986), SERT trafficking (Malison et al., 1998;
Joensuu et al., 2007), or promiscuous reuptake by other monoamine transporters (Fox et
al., 2008; Daws, 2009). These effects will be the focus of future studies.
It is, however, important to note that the large electrical stimulations necessary to
collect FSCV files cause aphysiological serotonin release. The stimulation allows us to
test the nuances of the regulation of the serotonin system; however, it is unlikely that
endogenous serotonin levels would spike to the levels we observe in our evoked
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experiments. Thus, we measured the ambient hippocampal serotonin response to ESCIT
in male and female mice using FSCAV. We selected the intermediary dose of 10 mg kg -1,

Figure 3.6: Effects of methiothepin pretreatment on ESCIT response. Control
stimulated 5HT is shown in black for (A) males (n = 4) and (B) females (n = 4) and 30
min following 0.1 mg kg-1 methiothepin (methio) are shown for (A) males (n = 4) in blue
and (B) females (n = 4) in red. Post-methiothepin pretreatment ESCIT (10 mg kg-1)
response is shown for (C) males in blue and (D) females in red. These are normalized to
ESCIT responses seen in Figure 3.4, shown in gray for (C) males and (D) females.
administered acutely. Interestingly, following administration of ESCIT, basal serotonin
increased in both male and female mice with no detectable differences between the sexes
(Figure 3.4).
Taken together, these data suggest that sex-mediated differences in serotonin
reuptake following ESCIT in the context of stronger autoreceptor control in females is
present only in response to the large electrical stimulation used with FSCV. This
aphysiological stimulation allows us to delve into the fine biochemical differences that
may exist within the synapse of male and female mice. These differences are in place to

73

protect against potential variation in modulation between the sexes but are only activated
under unusual circumstances. Therefore, on a physiological level, ESCIT appears to have
consistent effects across the sex lines in mice.
3.5

Conclusion
No distinction was found between the different stages of the estrous cycle, in the

hippocampus, in female mice. Furthermore, the average male and female control
serotonin signals and ambient levels were not significantly different from each other.
Modeling the average male and female serotonin evoked signals revealed a larger
autoreceptor effect in female mice, which was confirmed via methiothepin
administration. It is important to note that these autoreceptor differences may only be
visible under aphysiological conditions (such as electrical stimulation or disease).
Nonetheless, we showed that autoreceptor effects were not responsible for our finding
that acute SSRI are lesser able to slow reuptake in female mice. Therefore, while there is
evidence that under physiological conditions, there are no differences in hippocampal
serotonin; the data presented here emphasize considering sex as an important biological
factor when evaluating disease states and personalized treatment options.
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CHAPTER 4
IN VIVO HISTAMINE DYNAMICS IN MALE AND FEMALE MICE:
FAST VOLTAMMETRY REVEALS DIFFERENTIAL H3R
AUTOCONTROL4
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4.1

Abstract
Histamine plays an important role in the peripheral inflammatory response but

also serves as a neuromodulator implicated in circadian rhythms, feeding behavior,
learning & memory, and immunity. To date, most research on neuronal histamine has
focused on male models, leading to limited understanding of the female histamine
system. In this work, we aim to address this gap in histamine research by comparing
evoked histamine responses in male and female mice using fast-scan cyclic voltammetry
in the mouse posterior hypothalamus. Our data show evoked histamine is not statistically
different between male and female mice nor throughout the estrous cycle in female mice.
We found that histaminergic inhibition of serotonin via the histamine H3 receptor (H3R)
was conserved between the sexes. In both male and female mice, immepip (H3R agonist)
caused a decrease in evoked histamine release amplitude. Thioperamide (H3R antagonist)
caused an increase in histamine release in males but had no effect in female mice. We
postulate that in female mice there is tighter control over this H3R mechanism,
potentially for neuroprotective purposes. Overall, our results suggest that the histamine
systems are largely conserved between male and female mice. Pharmacological targeting
of H3R highlighted that, under aphysiological intervention, sex does appear to be an
important biological factor to consider during neurochemical studies and targeted medical
treatment of the histamine system.
4.2

Introduction
Histamine is a biological amine, stored in and released from immune cells like

mast cells (Ennis et al., 1981; Metcalfe et al., 1997) and T-cells (Jutel et al., 2001). In
addition to its roles in the immune system, histamine has also been identified as a
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neuromodulator (Haas et al., 2008; Rocha et al., 2014). The histamine cell body region,
the tuberomammillary nucleus (TMN), has projections that innervate throughout the
brain (Watanabe et al., 1983; Panula et al., 1989; Giannoni et al., 2009). Histamine H3
receptors (H3Rs), found primarily in the CNS, act as autoreceptors that control histamine
release (Arrang et al., 1987; Stevens et al., 2001) and histamine synthesis (Arrang et al.,
1987; Torrent et al., 2005; Moreno-Delgado et al., 2006) or as a post-synaptic
heteroreceptors that modulate release of other neurotransmitters like serotonin, dopamine,
acetylcholine, glutamate, GABA and peptide systems (Haas et al., 2008). Targeted H3R
treatments are used for neurological disorders such as Alzheimer’s disease (Tokita et al.,
2006). There is a growing trend that inflammatory diseases underlie many neurological
disorders (Passani and Blandina, 2011) and while its roles are not clear just yet, it is
likely that the histamine system will soon come under the pharmacological spotlight as a
therapeutic strategy owing to its role in both inflammation and neurotransmission
(Cacabelos et al., 2016; Hu and Chen, 2017). In this regard, it is of note that histamine, in
the periphery, has been shown to vary across the sexes (Rainville et al., 2018). For
example, there are suggestions that this amine is found at higher basal levels in females
(Leitch et al., 1956; Gustafsson et al., 1957; Kim, 1959) as a function of synthesis (Kim,
1959). Histamine is a neuroendocrine agent, modulating the release of hormones
including gonadotrophins (Sawyer, 1954; Endröczi and Hilliard, 1965; Donoso et al.,
1976; Libertun and McCann, 1976; Donoso, 1978). The hypothalamic concentrations of
histamine and its associated enzymes are found to vary through the estrous cycle
(Björklund et al., 1972; Snyder and Taylor, 1972; Maśliński et al., 1975; Orr and Quay,
1975).
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CNS histamine has previously been studied by using brain homogenates (Green
and Erickson, 1964; Taylor and Snyder, 1972), in vivo microdialysis coupled to high
performance liquid chromatography (HPLC) (Flik et al., 2015), and electrophysiology
(Ferretti et al., 1998). We developed a fast-scan cyclic voltammetry (FSCV) method to
selectively detect local histamine in vivo at high temporal resolution (Samaranayake et
al., 2016). We have previously found that stimulated histamine resulted in inhibition of
serotonin and showed this was modulated via H3Rs (Samaranayake et al., 2016). This
inhibitory control has also been shown by others (Schlicker et al., 1988; Threlfell et al.,
2004; Haas et al., 2008; Rocha et al., 2014).
In this paper, we extend our studies of histamine to female mice to elucidate any
differences that may exist in brain histamine between the sexes. We found no differences
in evoked hypothalamic neuronal histamine between male and female mice. In females,
we found no significant differences in histamine during the estrous cycle. When studying
H3Rs, no differences were found in histamine mediated serotonin inhibition across the
sexes however a robust difference was observed during pharmacological antagonism of
H3Rs. We thus show that in female mice, the histamine autoreceptor exerts tighter
control over histamine release and hypothesize that this a potential neuroprotective
mechanism. Revealing such subtle differences in control of neurotransmission are critical
when seeking novel pharmacological strategies.
4.3

Results

4.3.1

Evoked Hypothalamic Histamine in Male and Female Mice
Evoked hypothalamic histamine signals in male and female mice (n=29 each) is

compared in Figure 4.1. In Figure 4.1A the average evoked histamine trace is shown
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([HA] vs. time). We show the raw histamine data in Figure 4.1B,C for males and
females respectively. There is no statistical difference between the average maximum
amplitude/max stimulated release of histamine (p = 0.21) nor is there a difference in t1/2
of the histamine reuptake curve between the sexes (p = 0.67). These results are tabulated
in Figure 4.1D. Taken together, we can confidently state that evoked histamine response
in the hypothalamus is not significantly different in male and female mice.

Figure 4.1: Average evoked hypothalamic histamine in male and female mice. (A)
Averaged evoked histamine in male (blue, n=29) and female (red, n=29) is displayed.
SEM is shown as a lighter shade around the trace. Stimulation is marked by a gray box at
5-7 s. (B) Raw data for each male evoked release encompassed in the average is shown.
(C) Raw data for each male evoked release encompassed in the average is shown. (D) A
table comparing maximum amplitude and t1/2 in males and females and show no
statistical difference using a 2-tailed students t-test. Statistical difference was defined as p
< 0.05.
4.3.2

Hypothalamic Histamine Does Not Change Throughout the Estrous Cycle
Histamine was evoked in the posterior hypothalamus of female mice during each

of the different stages of the estrous cycle. No statistical differences were seen in the
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amplitude (p = 0.42) or t1/2 (p = 0.38) of the evoked histamine release and clearance from
any of the four estrous stages using an ANOVA (Figure 4.2). While we found no
statistical differences in these histamine signals across stages of the estrous cycle,
although we can visualize minute individual differences in each of these traces.
Statistically, we suggest that no stage of the estrous cycle is different when the data is
pooled or averaged.

Figure 4.2: Evoked histamine in the posterior hypothalamus in each stage of the
estrous cycle. The average evoked release of histamine (HA) of female mice in estrus
(red, n=23), metestrus (yellow, n=15), diestrus (green, n=8), and proestrus (purple, n=8)
are shown. Amplitude and t1/2 is shown in the table. An ANOVA was used to determine
statistical differences between cycle stages max amplitude (Amp max; p = 0.42) and t1/2 (p
= 0.38).
4.3.3

HA/HRH3 Mediated Inhibition of Serotonin in Male and Female Mice
The posterior hypothalamus is a unique region of the brain to apply FSCV as we

can measure both evoked histamine and the real-time, resulting inhibition of 5HT via the
H3 heteroreceptor (Samaranayake et al., 2016). Here, we averaged the histamine and
serotonin signals from 20 male and 20 female mice (Figure 4.3A,B). Both sexes display
similar inhibitory control of serotonin by histamine release. We found that the max
amplitude of both histamine and serotonin were not significantly different by sex (HA
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Ampmax: p = 0.82; serotonin (5HT) Ampmax: p = 0.64) (Figure 4.3C). We further
calculated that there is no statistical difference in the proportion of inhibition, determined
by the ratio of histamine release to the decrease in serotonin release in male and female
mice (p = 0.37) (Figure 4.3C). Thus, we suggest that histamine’s ability to modulate and
inhibit serotonin is not only conserved between the sexes it is comparable.

Figure 4.3: Average H3R-mediated inhibition of serotonin in male and
female mice. Histaminergic inhibition of serotonin in male and female mice
showing an average of 20 selected (A) male and (B) female mice. (C) A table is
included to show the average max amplitude of HA and 5HT as well as the ratio
of inhibition.
4.3.4

Pharmacology of the H3 receptors show sex-dependent differences
While Figure 4.3, shows no statistical differences in H3R-mediated serotonin

inhibition we wanted to further test how these systems, in male and female mice,
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responded to stress, specifically pharmacological intervention. We chose to explore this
H3R relationship by systemically administering H3R antagonists and agonists. Immepip,
a HRH3 agonist, was administered (i.p., 5 mg kg-1) following collection of control
histamine FSCV files in the posterior hypothalamus (Figure 4.4). Fifty min following
immepip administration, we saw decreases in the amplitude of evoked histamine release
in both male and female mice (Ampmax (µM): Male control: 7.66 ± 1.56, Male postimmepip: 5.10 ± 1.21 µM; Male: p = 0.03; Female control: 6.20 ± 0.87, Female postimmepip: 3.58 ± 0.51; Female: p = 0.005). We conclude that immepip has an effect in
both sexes although the large individual variability in evoked releases makes it difficult
to tease out visually.

Figure 4.4: Hypothalamic histamine response to H3R antagonist administration.
Average (A) male and (B) female control evoked histamine in the hypothalamus are
shown in blue. In green is the average evoked histamine 60 min following immepip
administration (i.p., 5 mg kg-1, n=5 each).
Thioperamide, a HRH4 and HRH3 antagonist, has been previously shown to
increase the amplitude of histamine release in male mice (Samaranayake et al., 2015).
Here, in Figure 4.5 we show that while the male response was maintained, the females
do not show this response to (i.p. 20 mg kg-1) thioperamide (Ampmax (µM): Male control:
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8.80 ± 2.76, Male post-thioperamide: 12.49 ± 4.36; Male: p = 0.021; Female control: 5.96
± 0.49, Female post-thioperamide: 6.00 ± 0.67; Female: p = 0.91; n=6 for both).
Following i.p. administration of thioperamide there is not a significant increase in max
amplitude of evoked release in females.

Figure 4.5: Hypothalamic histamine response to H3R agonist administration. The
control evoked histamine signal for (A) male and (B) female mice is shown in blue and
40-50 min following i.p. administration of thioperamide (20 mg kg-1) is shown in orange
for each (n=5 each).
The impaired ability of the female mice to respond to thioperamide challenge
(Figure 4.5) encouraged us to perform the following experiment. We administered first
immepip then thioperamide in female mice to determine if, by using FSCV, we could
detect agonist/antagonist relationship. Further we aimed to determine if the female mice
have a higher regulatory control over H3R or if the thioperamide dose administered was
failing to overcome a threshold to induce a neurochemical response. In Figure 4.6A,B
one can see that immepip decreases evoked histamine release (as shown in Figure 4.4)
and administration of thioperamide after immepip is able to nearly recover the max
amplitude of this signal to control levels and ablate the effects of the H3R agonist. Post-
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immepip thioperamide treatment does not, however, increase evoked histamine above
that of the initial control evoked histamine release in female mice (Figure 4.6B).

Figure 4.6: Effect of immepip pretreatment on thioperamide-induced histamine
response in female mice. (A) The average female evoked control hypothalamic
histamine signal is shown in blue. Then sequential measurements of histamine release 60
min following immepip administration (i.p., 5 mg kg-1, in green, n=5) and 40 min
following thioperamide administration (i.p., 20 mg kg-1, in orange, n=4) is shown. (B)
Average max amplitude for control, post immepip, and post thioperamide traces are
shown, amplitude statistically decreases following immepip (p = 0.005) and increases
following thioperamide (p = 0.13) to nearly that of the control signal (p = 0.83).
Statistical significance was determined using a student’s t-test and statistical significance
was defined as p < 0.05.
4.4

Discussion

4.4.1 Control Histamine Is Not Significantly Different Between the Sexes in the
Hypothalamus
Under control conditions, we do not see any differences in hypothalamic release
and reuptake of histamine in male vs. female mice (Figure 4.1). This finding is well
aligned with our previous work that compared hippocampal serotonin between the sexes
and found no statistical differences (Saylor et al., 2019). While not consistent in the
literature, this does differ from studies that suggest that histamine turnover and histamine
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CSF concentration is higher in females (Prell and Green, 1994) and other studies that
show lower histamine in females (Ferretti et al., 1998).
Importantly, the data that we present here is essentially raw and un-normalized
thus the almost near overlap between the average male and female response is striking.
This finding attests to the high level of conservation in neurochemical regulation
mechanisms across individual mice.
There has, in the past, been the intrinsic belief that there may be neurochemical
differences between the different stages of the estrous cycle that has limited the use of
females in research (Beery and Zucker, 2011). This belief may be even stronger for
histamine due to its potential role in neuroinflammation; the extent of immune reactivity
has been thought to depend on the different stages of the estrous cycle (Krzych et al.,
1978; Muñoz-Cruz et al., 2015). Thus, we compared evoked histamine in female mice
during different stages of the estrous cycle and found that histamine in each cycle was not
different from the average female response (Figure 4.2). This finding is not surprising
since in our own prior experience with measuring neurotransmitters with FSCV, we have
had to employ rather aggressive means to affect a significant but small change from the
homeostasis (Samaranayake et al., 2016; Saylor et al., 2019), these means, such as high
doses of SSRIs, correspond to profound behavioral alterations (Sánchez and Meier,
1997). Accordingly, it is not surprising to us that the average non-pathological response
is uniformly conserved across sexes, no matter the stage of the female estrous cycle.
4.4.2

Histaminergic Inhibition of Serotonin is not Statistically Different
We specifically choose to conduct our histamine neurochemical measurements in

the posterior hypothalamus due to an event that we previously noted in Srimal et al.
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(Samaranayake et al., 2016). We find that near the premammillary nucleus of the
hypothalamus we can simultaneously detect both evoked histamine release and the
resulting inhibition of serotonin. This process has been shown by others (Schlicker et al.,
1988; Threlfell et al., 2004; Haas et al., 2008; Rocha et al., 2014) as well as ourselves to
be a H3R mediated phenomenon (Samaranayake et al., 2016). In Figure 4.3, we show
that we have found no statistical difference in evoked histamine’s ability to inhibit
serotonin in male and female mice in the posterior hypothalamus. This suggests, as one
may infer, that the system is tightly controlled and, thus, highly conserved. It is important
to note that neurotransmitter levels must be highly regulated to maintain homoeostatic
balance but also because excess neurotransmitter can be neurotoxic (i.e. serotonin
syndrome).
4.4.3

H3Rs are More Tightly Autoregulated in Female Mice
H3Rs autoinhibit histamine release and heteroinhibit release of other

neurotransmitters (Haas et al., 2008). We pharmacologically targeted the H3R with
agonists and antagonists. Administration of the H3R agonist, immepip, appeared to
produce similar blunting of evoked histamine release in both male and female mice
(Figure 4.4).
Using thioperamide, an H3R antagonist (as well as H4 receptor antagonist), that
crosses the blood brain barrier (BBB), we were able to analyze H3R modulation of 5HT
in both male and female mice. Neurochemical results suggested that thioperamide
increased evoked histamine in male mice while failing to do the same in female mice
(Figure 4.5). This contrasts with previously published work that observed behavior
following thioperamide treatment and found similar effects in male and female rats (Ghi
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et al., 1999). However, other studies have suggested that stressor-induced increases in
histamine release may be lower in females that it is in males (Ferretti et al., 1998). This is
the first discrepancy we have uncovered in the histamine system between male and
female mice. We postulate that this could represent evidence that the histaminergic
system is more highly regulated/controlled in female mice and thus the stressor was not
enough to trigger the same biochemical mechanism that thioperamide did in male mice.
This increased control may have evolutionary underpinnings as it is often thought that
female animals may exhibit more homeostatic control and that female hormones, like
progesterone, have neuroprotective functions (Roof and Hall, 2000).
In Figure 4.6 we showed that pretreatment with immepip (and the resulting
decrease in evoked histamine) allowed thioperamide to increase evoked histamine in
females as seen in males, but only to a level akin with the control evoked histamine
release. Thus, suggesting that thioperamide treatment is only effective up to a certain
threshold in female mice (Figure 4.5). Here we believe that this truly emphasizes just
how much stress this female H3R system can withstand by using targeted
pharmacological attacks.
4.5

Conclusion
Histamine has essential roles in sleep-wake cycles, immunity, and learning,

however, it is difficult to study this transmitter in vivo. It has long been assumed that
histamine exhibits sex-dependent differences, however, it has historically been difficult to
measure these. Here, using fast voltammetric techniques we found no statistical
differences in evoked hypothalamic histamine between mice of different sexes nor female
mice in various stages of the estrous cycle in comparison to an average female response.
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Further, we find that H3R-mediated inhibition of serotonin, that we can simultaneously
detected, is not different in male and female mice. Administration of agents targeting the
H3R mechanism revealed that female mice exhibit tighter control over evoked histamine
and H3R agonist are only effective with H3R antagonist pretreatment. We find no
differences on the control level at near-physiological conditions (aphysiological
stimulation) suggesting that the histaminergic system is highly conserved in male and
female mice. The differences in response to targeted attacks on the system yielded
variable responses across the sexes reveals that sex is an important biological factor to
consider under stress from pharmacological challenge or disease states with elevated
activation of the immune system.
4.6
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CHAPTER 5
A VOLTAMMETRIC ANALYSIS OF ESCITALOPRAM EFFECTS ON
THE SERT MET172 MOUSE MODEL5
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5.1

Abstract
Psychiatric diseases, like depression, are becoming increasingly prevalent and

contribute substantially to global disease burden. One of the biggest obstacles facing the
treatment of depression is the gap in our understanding of how traditionally used
antidepressants, that have been shown to alleviate depression symptoms in most patients,
impose their effects on the biological system. Antidepressants, like selective serotonin
reuptake inhibitors (SSRIs) work by inhibiting the serotonin transporter (SERT)’s
reuptake of serotonin, thereby increasing available serotonin in the extracellular space. In
this work, I employ a SSRI-insensitive mouse model (SERT Met172) to explore the
mechanism of action of SSRIs as measured in vivo using carbon fiber microelectrodes to
detect changes in hippocampal serotonin neurochemistry in real time via fast scan cyclic
voltammetry (FSCV). My results suggest that SERT Met172, following SSRI
administration, show no slowing of serotonin reuptake, however, repeated measurements
resulted in the depletion of serotonin stores. Further testing revealed that serotonin
depletion may be, in part, due to the detrimental effects of repeated electrical stimulation
and/or off-target effect of the SSRI on vesicular monoamine transporter (VMAT). The
effects of SSRIs on VMAT may also explain the increase in amplitude of release that
accompanies the SERT-mediated slowing of reuptake seen following in vivo
administration of an SSRI in wild type animals. Taken together, by employing an SSRI
insensitive mouse model and in vivo neurochemistry studies I uniquely probed the
serotonergic system and more specifically determined the mechanism of action of these
commonly prescribed antidepressants.
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5.2

Introduction
Psychiatric diseases, like depression, contribute greatly to the global disease

burden. Depression effects a staggering number of individuals, estimated to be around
300 million in 2015, and is becoming increasingly more prevalent (World Health
Organization, 2017). With this increase in prevalence comes a vast disability (World
Health Organization, 2017) and economic (Trautmann et al., 2016) burden on the global
community. Given the large impact of depression on society it is of concern that this
disease remains, in large part, a mechanistic mystery.
As previously reviewed in Chapter 1, one of the main hypotheses that persists in
the depression research field is the monoamine hypothesis where in it is predicted that
depression

is

the

result

in

dysregulation

of

monoamine

neurotransmitters

(norepinephrine, dopamine, and/or serotonin (5HT)). In particular, serotonin, has long
been suspected to be a keystone player in the pathogenesis of depressive illness. In
support of this concept, cerebrospinal fluid (CSF) serotonin levels are often decreased in
patients with depressive illness (Asberg et al., 1976b; Asberg et al., 1976a; Roy et al.,
1989), acute serotonin depletion can elicit reemergence of depression symptoms
(Quintana, 1992; Delgado et al., 1999), drugs that increase serotonin levels have shown
efficacy in the treatment of depression (Anderson, 1998; Trivedi et al., 2006), and studies
have linked genetic variants of the serotonin transporter (SERT) to depressive illness
vulnerability (Karg et al., 2011). Further, genetic polymorphisms in the SERT transporter
gene has been linked to impaired response to stressors suggesting a strong gene by
environment interaction may be present at this genetic locus (Caspi et al., 2003; Karg et
al., 2011).
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To better understand depression pathology, this work examines how SSRIs, the
most commonly prescribed antidepressants, exert their pharmacological effects via
binding to and inhibiting SERT-mediated reuptake of serotonin back into the cell
following neurotransmission with varying degrees of binding and efficacy. In this
manner, SSRIs serve to increase extracellular serotonin levels in an effort to restore
synaptic plasticity and thereby reduce symptoms of depressive illness. Unfortunately,
SSRIs only work in about 1/3 of patients (Trivedi et al., 2006). Nonetheless, a large
chunk of depression research is focused on determining the role of SERTs in pathology
and treatment.
Previous studies on the mechanism of SSRIs have employed SERT knockout
mice, which exhibit depressive-like behaviors (Lira et al., 2003), decreased serotonin
concentration (Bengel et al., 1998), decreased serotonin neuronal content (Lira et al.,
2003), varied dorsal raphe firing (Lira et al, 2003), and altered serotonin receptor
expression (Rioux et al., 1999; Fabre et al., 2000; Li et al., 2000; La Cour et al., 2001).
This SERT knockout model employs genetic modification that deviates from “normal”
physiological SERTs. Thus, a mutant mouse with a single amino acid mutation near the
SERT serotonin binding site (Ile172 in human and mouse substituted with Met172) that
impairs the binding of high affinity antagonists, such as the SSRIs was generated (Henry
et al., 2006; Nackenoff et al., 2016). This mouse model with a knock-in substitution that
impedes the binding of some SSRIs to the SERT transporter without impairing SERT
function itself is arguably more physiologically relevant (Henry et al., 2006; Thompson et
al., 2011). Accordingly, I employed this SERT Met172 mouse model to resolve the
effects of acute SSRI administration on serotonin neurochemistry. Further, I aim to
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elucidate if SSRIs have effects on other parts of the neurochemical system such as the
vesicular monoamine transporter (VMAT), a vesicular packaging enzyme, that has been
shown to respond SSRI administration. In order to accomplish this study, I used fast-scan
cyclic voltammetry at carbon fiber electrodes to study real time changes in serotonergic
neurochemistry.
5.3

Results

5.3.1

Hippocampal 5HT Response to Acute SSRI Administration
FSCV was used to determine average evoke hippocampal serotonin in wild type

(WT), Met172, and heterozygous (HET) mice (Figure 5.1A-C). No differences were
seen in control evoked signals nor the generated color plots (Figure 5.1D). Thirty min
following i.p. administration of 10 mg kg-1 ESCIT reuptake is slowed only in WT mice
(t1/2: control 2.4 ± 0.4, post-ESCIT 11.8 ± 3.0; p = 0.005). ESCIT administration also
elicits a visual increase in the amplitude of evoked release in WT mice, although this
increase is not statistically significant (Ampmax: control 17.2 ± 4.6, post-ESCIT 25.2 ±
8.3; p = 0.122) (Figure 5.1A). Conversely, HET and Met172 mice show minimal
changes following ESCIT (Figure 5.1B,C). Importantly, not only did ESCIT fail to
increase amplitude of serotonin evoked release in Met172 mice, it decreased amplitude
over time and the evoked serotonin release was greatly reduced or depleted by about 60
min in most mice (Figure 5.1E). Overall, these results confirm that SERT Met172
knock-in mice do not show evidence of SERT inhibition following the administration of
ESCIT. Interestingly, this modification to the SERT limits binding of some but not all
SSRIs. As shown in Figure B.1, Met172 mice still respond to the SSRI paroxetine
(Henry et al., 2006).
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Figure 5.1: ESCIT administration does not slow 5HT reuptake in SERT Met172
mice. (A-C) Averaged control evoked hippocampal 5HT is shown in gray and 30 min
following i.p. administration of ESCIT (10 mg kg-1) is shown in violet for WT, Met172,
and HET mice respectively (n = 5 mice for each, n=4 for Met172 post ESCIT). (D) An
example of a generated color plot for hippocampal 5HT is shown. Stimulation is marked
using a small green or gray box at 5-7 s (A-D). (E) Amplitude of evoked 5HT following
ESCIT administration are shown from control (0 min) to 60 min post ESCIT. SEM is
shown as a shadow (lighter color) around each trace or with traditional error bars.
The decrease in evoked serotonin release in Met172 mice following ESCIT may
imply a decrease in basal serotonin levels. To test this, FSCAV was used to measure the
effects of ESCIT on basal serotonin in WT and Met172 mice. There was no difference in
pre-FSCAV evoked release nor basal serotonin concentration in WT and Met172 mice
(Figure 5.2A-C). An i.p. injection of saline (at 30 min) was used as an injection control
did not elicit a change in basal hippocampal serotonin levels (Figure 5.2C). At 60 min,
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ESCIT administration (i.p., 10 mg kg-1) elicited the expected increases in basal serotonin
levels in the hippocampus of WT mice, increases that are not seen in Met172 mice
(Figure 5.2C). Similarly, I did not observe a decrease in basal serotonin that the decrease
in amplitude of evoked serotonin release following ESCIT in Met172 mice would predict
(Figure 5.1C). Following 60 min of basal analysis, post-ESCIT FSCV files show that
WT mice have increased amplitude and slowed reuptake of evoked hippocampal
serotonin akin to a traditional SSRI response (Figure 5.2A) while Met172 mice have a
mild increased amplitude of release (Figure 5.2B), contrary to what was seen in Figure
5.1C.

Figure 5.2: Basal 5HT response to ESCIT administration in SERT
Met172 mice. Evoked control 5HT (gray) and evoked 5HT postESCIT (i.p., 10 mg kg-1) basal measurements (blue) in (A) WT mice
(n=4) and (B) Met172 mice is shown (n=5). (C) Basal 5HT responses
in both WT (blue) and Met172 (green) mice to ESCIT administration
are shown (n=5). Statistical significance was defined as p < 0.05.
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5.3.2

Repeated MFB Stimulation Effects on Extracellular Hippocampal 5HT
To test the mechanistic basis for the decrease in evoked release seen following

stimulation (for FSCV measurements) and ESCIT administration in Met172 mice, I
examined the effects of repeated MFB stimulation. In this regard, basal hippocampal
serotonin was measured during a FSCV stim experimental paradigm. Figure 5.3 shows
the average basal concentration for 10 min of control files, then following a stimulation
paradigm with stimulations at 10, 15, 20, 30, 40 min; and basal collections were
continued for an additional 60 min following the last stimulation at 40 min. Basal
hippocampal serotonin increases following the first stimulation at the 10 min time point
and remains elevated until the next stimulation five min later. This elevated serotonin is
maintained till the next stimulations spaced 10 min apart. It takes approximately 20 min
for basal serotonin to return to control levels following this FSCV experimental paradigm
(Figure 5.3).

Figure 5.3: Stimulation during basal 5HT analysis. Basal 5HT in
WT mice was recorded every min while electrical stimulation was
applied, following 10 min of baseline collection, at 10, 15, 20, 30, and
40 min. Basal 5HT was monitored for 60 min post stimulations until
5HT returned to near baseline (n=4). Statistical significance was
defined as p < 0.05.
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5.3.2

Effect of SSRI on VMAT
To explore potential off target effects of ESCIT, I targeted VMAT using the

reversible VMAT inhibitor tetrabenazine. Figure 5.4 shows the effect of VMAT preinhibition prior to ESCIT administration. Tetrabenazine (10 mg kg-1) mildly decreased
stimulated serotonin release in both WT and Met172 mice (Figure 5.4A-D) while vehicle
pretreatment (10% DMSO in sterile saline) exhibited similar 5HT levels as control
evoked 5HT. All groups were then administered ESCIT (i.p., 10 mg kg -1). As shown in
Figure 5.1A and Figure 5.2A with slowing of reuptake and a mild increase in amplitude
in WT mice. However, hippocampal 5HT concentrations did not decrease further
following SSRI administration in tetrabenazine-treated Met172 mice (Figure 5.4B,D). In
Met172 mice, pretreatment with tetrabenazine ameliorated some of the ESCIT-induced
decrease in stimulated 5HT release illustrated in Figure 5.1C.
5.4

Discussion

5.4.1

ESCIT Administration Decreased Evoked 5HT in Met172 Mice
SSRIs bind to and inhibit SERT-mediated reuptake of serotonin with varying

degrees of efficacy. Since different generations of SSRIs bind to different places on the
transporter, genetic modifications can be made to make SERTs insensitive to certain
SSRIs. SERT Met172 mice are genetic knock-in mice with a single amino acid
substitution that makes them insensitive to some SSRIs including ESCIT. As such,
Met172 mice an invaluable tool for are targeted neurochemical studies to explore the
mechanism through which these drugs impose their neurochemical effects (Henry et al.,
2006).
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Figure 5.4: Tetrabenazine treatment reduces the efficacy of ESCIT in WT
and Met172 mice. Evoked hippocampal 5HT release is shown for control signals
in blue, post DMSO vehicle controls (averaged over 30 min) in gray, 30 min post
tetrabenazine (i.p., 10 mg kg-1) in orange, and 30 min post ESCIT (i.p., 10 mg kg1) administration in blue for (A) WT and (B) Met172 mice (n=4 for each). (C-D)
shows average max amplitude for each animal after each drug administration.
Statistical significance was defined as p < 0.05.
ESCIT administration visually decreased the amplitude of evoked hippocampal
serotonin release in Met172 mice at 30 min post ESCIT and evoked serotonin was nearly
depleted by 60 min in these mice (Figure 5.1C,E). Meanwhile, WT mice exhibit the
increase in 5HT release and slowed reuptake following ESCIT administration (Figure
5.1A). Heterozygous mice injected with ESCIT show little change excluding a mild
increase in amplitude (Figure 5.1B). My findings in Met172 mice suggest that there may
be: 1) a change in extracellular serotonin in response to ESCIT, potentially by ESCIT still
binding to this modified SERT as suggested in previous work (Thompson et al., 2011); 2)
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unintentional biological changes as a result of the aphysiological MFB stimulation used
in tandem with FSCV; or 3) off-target effect of the SSRI on other enzymes, transporters,
or molecules. The subsequent experiments in this study tested these possibilities.
5.4.2

ESCIT Administration Does Not Change Basal Serotonin in Met172 Mice
I employed FSCAV to test hypothesis 1 by examining extracellular serotonin

levels following ESCIT administration. Importantly, the control values of basal serotonin
in these mice fell within the range of hippocampal serotonin levels previously determined
in C57 mice (Abdalla et al., 2017). Basal serotonin levels were not different between the
groups (WT and Met172). WT mice show an SSRI response similar to that previously
shown (Saylor et al., 2019) with an increase in hippocampal serotonin, while Met172
mice exhibited no changes in extracellular serotonin levels following ESCIT treatment
(Figure 5.2C). Analysis of basal serotonin in response to ESCIT administration also
revealed another unique event. Following the basal experiment in Figure 5.2 evoked
release was measured using FSCV. FSCV files after basal measurements following
ESCIT administration show a SSRI response in WT mice (increase in amplitude of
release and slowing of reuptake; Figure 5.2A) and a very mild increase in amplitude of
release in Met172 mice (Figure 5.2B). This suggests that MFB stimulation reveals a
mechanistic distinction between Met172 mice’s response to ESCIT in Figure 5.1B and
Figure 5.2B. In this regard, using methods that do not employ stimulation (namely
FSCAV) with ESCIT administration, I did not see the depletion of serotonin seen with
experiments with both stimulation and ESCIT (Figure 5.1C). Instead, I show that
following FSCAV measures of ESCIT response in Met172 there is a mild increase in
amplitude when stimulation returns. Taken together, this suggests that the FSCV
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paradigm, unrelated to the ESCIT administration, may have been responsible for the
depletion of serotonin seen in Met172 mice as this phenomenon is not conserved using,
non-stimulation requiring methods like FSCAV.
5.4.3

Repeated Stimulation Increases Extracellular 5HT
Previously studies have shown that repeated electrical stimulation can cause

facilitation of some neurotransmitters like dopamine (Kita et al., 2007), while other
neurotransmitters like serotonin show depletion (Hashemi et al., 2009). Serotonin, is
predicted to deplete due to tighter serotonin autoreceptors control (Hashemi et al., 2009).
To test what in the experimental paradigm might be different within the serotoninergic
system in stimulation/FSCV and non-stimulation/FSCAV experiments, I performed the
two methods simultaneously. In this work, I collected FSCAV measurements every min
while performing the traditional 0, 5, 10, 20, 30 min post-drug stimulation paradigm. In
Figure 5.3, stimulation increases extracellular serotonin levels in a manner that is beyond
the capacity of the system to recover from before the next stimulation occurs, regardless
of whether that stimulation is 5 or 10 min apart. This is especially apparent with
prolonged stimulation schemes. This is incredibly important because with traditional
FSCV 5HT measures we only wait 10 min between evoked files, which may not be
enough to allow the serotonergic system to fully recover thereby producing an innate bias
for each file to be different from the last. We postulate that this may contribute, in part, to
the depletion in serotonin associated with ESCIT administration in Met172 mice.
However, when we observe this maintained elevation in extracellular serotonin only as a
pitfall of our technique, we overlook something that makes our technique unique.
Elevated serotonin, in response to SSRIs is predicted to change neurochemistry (Blier
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and Bouchard, 1994; Benmansour et al., 1999; Czachura and Rasmussen, 2000) and in
clinical settings this increase in synaptic concentration of serotonin is predicted to require
multiple doses of SSRIs to restore brain plasticity. This requirement of the restoration of
synaptic integrity is pinpointed as a potential reason that chronic administration is
required for antidepressant effects. Here, we suggest that our stimulation may elevate
serotonin aphysiologically but may allow us to better model “chronic” SSRI
administration. Further testing will be required but this does present an interesting
pharmacological opportunity. This is particularly relevant given the increase in deep
brain stimulation treatments for disease like treatment resistant depression (Mayberg et
al., 2005).
5.4.4

Targeted VMAT depletion blunts ESCIT induced changes
We hypothesized that the depletion in serotonin seen in Met172 mice following

ESCIT administration as shown by FSCV measurements could be explained by off-target
effects of ESCIT. Changes in autoreceptor function could occur, however, it seems
unlikely given the speed in which we see serotonin depletion occur. We also considered
that it could be a change in reuptake, synthesis, or metabolism of serotonin, all of which
we could exclude based on our FSCV and FSCAV measurements. We, thus, postulate
that the depletion could be due to SSRI effects on VMAT. VMAT 1 (found
predominantly in the periphery) and 2 (found predominantly in the CNS) are responsible
for the transport of dopamine, adrenaline, noradrenaline, histamine, and serotonin into
synaptic vesicles (Erickson et al., 1992; Henry et al., 1994; Liu and Edwards, 1997).
Previously published work identifies VMAT as another molecule that could be affected
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by SSRI administration (Yasumoto et al., 2009). Critically, decreased VMAT function
could result in depletion of monoamines including serotonin.
To address the potential off-target effects of ESCIT, I targeted the VMAT using
the reversible inhibitor tetrabenazine. Pre-treatment of Met172 and WT mice with
tetrabenazine (a reversible VMAT 2 inhibitor) (Hayden et al., 2009) was able to perturb
the ESCIT and stimulation induced “depletion” of serotonin that we see in Met172 mice
in Figure 5.1C (Figure 5.4B,D). Further, tetrabenazine pretreatment appeared to blunt
the SSRI induced increase in amplitude in WT mice, suggesting that SSRI-interactions on
VMAT may, at least in part, be responsible for those amplitude increases (Figure
5.4A,C).
In support of our findings, genetic or environmentally induced changes in VMAT
expression and function has been linked to many diseases like Parkinson’s disease and
depression (Miller et al., 1999; Nunes et al., 2013). Additionally, VMAT 2 knock-out
mice exhibit depressive like-behaviors further supporting the link to psychiatric disease
(Fukui et al., 2007). Overall, this suggests that off target effect of SSRIs on VMAT,
resulting in depletion of monoamines, may be counteracting their effects at SERT to
increase serotonin. Importantly we find that while SERT Met172 mice are insensitive to
SSRIs at the SERT, where their pharmacological effect is expected, it is clear that there
are some off-target effects of these agents that have yet to be fully accounted for.
5.5

Conclusion
In conclusion, SERT Met172 knock-in mice have a single amino acid substitution

that makes them insensitive to some SSRIS. We found Met172 mice were resistant to
SSRIs (ESCIT)-induced inhibition of SERT. Further, I found that SSRI administration
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decreases evoked serotonin in Met172 mice, which is likely a result of many factors
including the aphysiological stimulation used to evoke serotonin release for FSCV
analysis and interactions of the SSRI on VMAT and other molecules and not due to
SSRI-induced fluctuating levels of basal serotonin. Collectively, these findings work to
further elucidate the mechanism of action of ESCIT, and further our understanding of
depression and progress towards more targeted and effective depression treatments.
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6.1

Abstract
Antidepressant treatments, like selective serotonin reuptake inhibitors (SSRIs) are

widely prescribed to treat the growing population of depressed patients. SSRIs, like
escitalopram, aim to increase extracellular concentrations of the monoamine
neurotransmitter serotonin via inhibition of the serotonin transporter (SERT).
Unfortunately, SSRIs do not work in all patients and have a delay in clinical efficacy.
However, it is difficult to improve a drug whose mode of action remains largely
unknown. Therefore, we employ fast-scan cyclic voltammetry to measure in vivo (mouse)
and in vitro (stem cell) response to escitalopram. We determine that the serotonin system
responds differently over time in response to different doses of escitalopram.
Specifically, we find that medium-high doses of escitalopram (3 or 10 mg kg-1) in vivo
and 1.0 µM in cell culture induce a rapid increase in reuptake before reuptake slows
following SSRI treatment. We confirmed using confocal imaging of SERT activity at the
cell surface that this increased SERT activity may be linked to a rapid overexpression of
SERT immediately following SSRI administration to counteract drug actions. This is
quickly followed by an under expression of SERT and slowing of serotonin reuptake and
increases in extracellular serotonin. These results suggest that SERT number and function
are dynamic following escitalopram administration and an improved understanding of
these fluctuations may improve our understanding of the mode of action of commonly
prescribed antidepressants.
6.2

Introduction
Selective serotonin reuptake inhibitors (SSRIs) which are one of if not the most

commonly prescribed pharmaceutical agents in the world (The Mayo Clinic, 2019).
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These modern antidepressants are designed to rapidly and competitively inhibit the
serotonin transporters (SERTs), with the goal of increasing extracellular serotonin levels
in the brain. Lower extracellular serotonin levels have been long postulated to underlie
the behavioral manifestations of depression (Belmaker and Agam, 2008; Krishnan and
Nestler, 2008). SSRIs have well established disadvantages. One of the most peculiar
aspects of SSRI therapy is the delayed (often several weeks) onset of clinical action
(Tollefson and Holman, 1994; Stahl, 2000; Thase et al., 2001; Kasper et al., 2006).
During these weeks, patients often feel even worse and have an increased risk of suicide
(Jick et al., 2004; Yuan et al., 2019).
In a bid to speed up the clinical process, researchers have been exploring the
underlying causes of this delay. Theories include serotonin autoreceptor desensitization
(Blier and De Montigny, 1994; Hervás et al., 2001), SERT internalization (Lau et al.,
2008; Steiner et al., 2008; Lau et al., 2009; Descarries and Riad, 2012), and neurogenesis
(David et al., 2009; Mahar et al., 2014). It is fairly well accepted in the antidepressant
community that a clinical endpoint of SSRI efficacy is SERT internalization. Researchers
postulate that over several weeks of chronic exposure, SERTs internalize and this leads to
increased extracellular serotonin levels that alleviate the symptoms of depression.
However, the clinical delay issue with this theory remains.
In our work, we see that acute SSRIs do increase evoked serotonin levels after
around 10 minutes (Saylor et al., 2019). In this work, we use a suite of fast
electrochemical, optical, and mathematical tools to observe dynamic responses to acute
escitalopram (ESCIT), both in vivo in mice and in vitro in human derived iPSCs. We
find, in vivo, that a rapid (within 5 minutes), dose-dependent reaction to acute SSRI is an
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increase in the rate of serotonin reuptake. We model this increased rate as a function of a
temporary increase in the number of SERTs. Then using stem cells differentiated into
serotonin neurons and confocal imaging of SERT expression we find that activated cells
rapid reaction to ESCIT is to increase the number of SERTs on surface.
We thus show a rapid compensatory mechanism, capturable only by our fast tools,
that aims to increase SERT expression, presumably, to counteract the SSRI’s effects in
increasing extracellular serotonin. For an acute dose, this compensation is active for
around 10 minutes and is dose dependent, being overrun more quickly at higher doses.
These results beg the question of the role of this compensatory mechanism in humans
receiving a much lower, chronic dose and whether this contributes to the temporal delay
of SSRI action.
6.3

Results

6.3.1

Characterization of Acute Low Dose Escitalopram with FSCV and FSCAV
Evoked hippocampal serotonin was measured in mice and analysis of the effects

of a low dose of ESCIT were determined. In Figure 6.1A,B representative color plots of
control and 60 min post low dose ESCIT administration (i.p., 1 mg kg-1) are shown. The
green serotonin event can be seen in both color plots although the event persists in
duration notably longer in the post ESCIT color plot. Evoked serotonin was measured for
2 hrs post ESCIT and average signals at control, 0, 5, 30, 60, 90, and 120 min postESCIT can be seen in Figure 6.1C. By 20 min the rate of serotonin reuptake had been
slowed (p = 0.015) and remained slow for the duration of data collection (120 min)
suggesting that the SSRI was successfully inhibiting SERT. In Figure 6.1D,E, we note
that following low-dose ESCIT administration we see a fairly consistent increase in the
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average t1/2 or clearance rate and in the average maximum amplitude of evoked release
until they both plateau. Additionally, we analyzed the effect of low-dose ESCIT (i.p., 1
mg kg-1) on basal hippocampal serotonin and found that ESCIT increased basal serotonin
significantly at 30 and 60 min post administration (p = 0.024 and p = 0.003 respectively)
(Figure 6.1F).

Figure 6.1: Evoked and basal 5HT response to a low dose of ESCIT. An example
color plot and CV are shown for a (A) control evoked hippocampal signal and (B)
evoked signal 60 min following ESCIT administration (i.p., 1 mg kg-1, n=4).
Stimulation is denoted by the green box under the color plots (5-7 s). (C) The average
evoked release of hippocampal 5HT at 0, 5, 30, 60, 90, 120 min following 1 mg kg -1
ESCIT is shown. In (D), the average t1/2 is shown vs. time in response to ESCIT. In
(E), the average Ampmax is shown vs. time in response to ESCIT. (F) The effect of
ESCIT administration on extracellular serotonin levels as determined using FSCAV.
Statistical significance was determined using a 2-tailed student’s t-test (p < 0.05).
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6.3.2

Dynamic Escitalopram Dose Response
An acute dose response to a commonly prescribed antidepressant, ESCIT was

conducted using FSCV to measure resulting changes in evoked hippocampal serotonin.
ESCIT was administered i.p. at 3, 10, 30 mg kg-1 doses and neurochemical effect on
stimulated serotonin release and reuptake were monitored for two hrs following drug
administration in mice (Figure 6.2A-C). Notably, we saw a marked by an increase in the
amplitude of stimulated release as well as a slowing of serotonin reuptake of serotonin
after 10 min with all ESCIT doses. Upon closer examination of this data we found that at
the earliest time points following medium SSRI administration (at 5 min in the 3 and 10
mg kg-1 doses) some of the animals actually showed a faster reuptake before the reuptake
eventually slowed (see Figure 6.2A,B). In Figure 6.2D the normalized uptake rate at
each dose is shown vs. time. Here it is apparent that the 3 and 10 mg kg -1 ESCIT doses
exhibit, first, an increase in reuptake followed by the SSRI-induced slowing in uptake at
5 min post-ESCIT. This is not observed in the higher dose (30 mg kg-1). To probe this
system further, basal serotonin was also measured in response to three different ESCIT
doses (1, 3, 10 mg kg-1). Here we observe that ESCIT administration (regardless of the
dose) increases hippocampal serotonin, visually we can further detect a slight delay in
ESCIT-induced serotonin increases. In fact, in the 10 mg kg-1 dose for example it takes 8
min before basal serotonin is consistently different from the average control (p = 0.008).
6.3.3

Dynamic Escitalopram Dose Response
ESCIT dose response was repeated in human iPSCs. FSCV was used to measure

evoked serotonin events in cells bathed in three doses of ESCIT (0.1, 0.5, and 1.0 µM
ESCIT) for 75 min following drug administration (Figure 6.3A-C). Following each dose
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Figure 6.2: ESCIT dose response in vivo. An ESCIT dose response is shown in female
mice: (A) 3, (B) 10, (C) and 30 mg kg-1 ESCIT (i.p., n=4 each). (D) The normalized
reuptake rate for the in vivo dose response is shown for each dose over a 2 h duration
post-ESCIT. (E) The basal serotonin responses to three ESCIT doses (1, 3, 10 mg kg -1) is
shown. An injection of saline (vehicle control) was administered at 30 min and ESCIT
was administered at 60 min (n=5 mice for 1, 3 mg kg -1, n=10 for 10 mg kg-1).
of ESCIT there is a visually detectible slowing of serotonin reuptake at 75 min. Similar to
that seen with the in vivo dose response in Figure 6.2, we observe that the in vitro dose
response shows mildly increased reuptake at the early time points (5 min post-ESCIT)
before slowing of reuptake occurs (Figure 6.3A,C). This can be better visualized in
Figure 6.3D were increased normalized uptake can be seen in the 0.1 and 1.0 µM ESCIT
doses at the 5 min time point prior to slowing in uptake rate. Next, real time
immunofluorescent studies of SERT dynamics were completed. Preliminary data here
suggests that SERT number increases initially at the membrane following SSRI
administration.
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Figure 6.3: ESCIT-induced changes in 5HT reuptake and SERTs in iPSCs. An
ESCIT dose response is shown in mouse IPSCs: (A) 0.1, (B) 0.5, (C) and 1.0 µM ESCIT
(n=3 each). (B) The normalized reuptake rate for the in vitro dose response is shown for
each dose over a 75 min duration post-ESCIT. (E) Preliminary data in human iPSC
suggests that SERT overexpression may occur before internalization.
6.4

Discussion

6.4.1

Acute Low Dose Escitalopram has a Predictable Mode of Action on Evoked

and Ambient Serotonin
One of the major problems that surround current antidepressant treatments today
is how little we know about their mode of action and our limited understanding of their
effects on the pathology of depression. We postulate that this greatly contributes to why
SSRIs show a delay in clinical efficacy. SSRIs work by inhibiting SERT to increase
extracellular serotonin to alleviate depression. We and others have confirmed that in vivo
or in tissue slices that SSRIs are able to inhibit SERT and slow serotonin reuptake (John
and Jones, 2007; Saylor et al., 2019). This is similar to dynamics seen with the dopamine
transporter (DAT) following inhibition (Hashemi et al., 2012). In this work, we see that
the response to a low dose of ESCIT (1 mg kg-1, Figure 6.1) mirrors that seen in in vitro
SERT studies and DAT studies. However, this is a low dose so we expanded our study to
include higher ESCIT doses.
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6.4.2

Dynamic Compensatory Serotonin Mechanisms are Triggered with Mid to

High Escitalopram Doses
Increasing the dose of ESCIT proved to be a much more challenging story to
understand. We find that post-ESCIT administration (of a medium to high dose, Figure
6.2) the dynamics in serotonin reuptake are much more variable and unlike the low dose
do not just continue to increase in amplitude and slow reuptake with time. First, we see
that, initially, at the medium doses that reuptake is sped up before it slows down.
We postulate that this dynamic response is due to the brain’s attempt to maintain
homeostasis following SSRI administration. It is, therefore, likely that during this time
SERTs are trafficked to the surface to address the SSRI-induced increases in serotonin
before they are overwhelmed and internalized. This internalization process has been
previously described (Lau et al., 2008; Lau et al., 2009). The initial increase has not been
previously shown, however, other studies have shown that following acute inflammation
SERTs can increase their efficiency (Zhu et al., 2006). Importantly, these studies point
out the capacity of SERTs to rapidly adjust in number and function following changes to
their environment.
In support of the initial bout by SERTs to homeostatitically regulate serotonin we
see that basal serotonin does not increase immediately after SSRI administration and can
take about 8 min before extracellular hippocampal serotonin is statistically different from
the control level even though we see reuptake slowing as early as 5 min. Critically, the
initial 0-10 minutes period following SSRI administration is where the increase in
reuptake is able to counter the increasing ambient levels to keep them at homeostasis.
After this time, SERTs are overwhelmed and start to internalize. In further support of this
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theory, when the we dose of ESCIT is increased from 1 to 3 mg kg-1, we do not see much
change how ambient serotonin increases, predictably due to the compensatory
mechanisms that are triggered. It is only at the higher dose of ESCIT that we are able see
increases in the basal serotonin levels (likely due to higher levels of SERT
internalization). This dynamic ESCIT dose response revealed a unique trend in SERT
quantity/function that would otherwise have been overlooked by a traditional dose
response.
6.4.3

Rapid Trafficking of SERT Modulates Regulation of Extracellular Serotonin
To further test what is happening to SERT number and function rapidly following

SSRI treatment we employed human iPSCs. Using FSCV we analyzed the evoked
serotonin in response to three doses of ESCIT and found a similar pattern (Figure 6.3) to
that which we saw previously with the in vivo dose response. Specifically, at the early (5
min) time point we see that at some doses reuptake speeds up before it slows down
(shown at 75 min time point). Preliminary data looking at SERT number following
ESCIT suggests that acute SSRI exposure increases SERT number (data not shown).
Overall, we see that with cells, the first response to acute ESCIT administration is to
increase SERT expression. This mechanism is short lasting in these acute models because
the system is rapidly overwhelmed with the high dose of SSRI. We, therefore, postulate
that this might be happening in vivo and could account for the delay in clinical efficacy of
SSRIs. Moving forward this work suggests that, clinically, it might be worth considering
large initial doses followed by follow up doses (similar with that used with ketamine for
treatment-resistant depression).
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6.6

Conclusion
Antidepressant treatments, like SSRIs have been shown to have efficacy in

treating depression but their mode of action remains largely unknown. One of the main
drawbacks of this therapeutic option is that SSRIs have a long delay in clinical efficacy
and for many patients, things get worse before they get better. In this work we suggest,
using a in vivo and in vitro dose response to ESCIT, that the response of SERTs to
pharmacological intervention is dynamic. We postulate that rapidly following SSRI
administration SERT number and function are increased at the surface resulting in
increasing reuptake speed to homostatically regulate extracellular concentration of
serotonin. This process is quickly overcome using high doses of ESCIT and it is
suggested that SERTs internalize in response. Thus, we emphasize the need to improve
our understanding of current antidepressant treatments before expanding to new ones.
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7.1

Abstract
Commonly prescribed antidepressants, like selective serotonin reuptake inhibitors

(SSRIs), inhibit the serotonin transporter. Pharmacologically, this is an attempt to
increase extracellular serotonin levels that, as per the monoamine hypothesis of
depression, are predicted to be lowered during depression. Serotonin’s role in depression
remains, in large part, a mystery which explains why SSRIs have low clinical efficacy
and treatments have not been improved upon over the decades. New research implies a
potential role for inflammation in the low efficacy of antidepressants, further pressing the
need to understand how SSRIs interact with serotonin in the brain. Here we employ fast
electrochemical tools, developed in our lab, to investigate the nexus between serotonin,
inflammation, and SSRI administration. Upon acute lipopolysaccharide (LPS)
administration we find robust decreases in extracellular serotonin in the mouse
hippocampus. We postulate that this lowered level is due to increased activity of brain
histamine acting on the histamine H3 receptors that inhibit serotonin release. Importantly,
we observe that LPS-induced inflammation impairs the ability of an SSRI to increase
extracellular serotonin. We suggest that this is a result of the SSRIs’ off-target inhibition
of histamine reuptake. In support of this, a targeted decrease in histamine synthesis could
increase SSRI chemical efficacy to increase extracellular serotonin levels. Using an
unpredictable chronic mild stress depression (CMS) model that is associated with chronic
elevation in inflammation state we again see robust decreases in extracellular serotonin in
the hippocampus of mice. Additionally, CMS-treated mice show impaired SSRI-induced
changes in extracellular serotonin. Again, co-administration of a histamine synthesis
inhibitor could rescue this blunted response. These results suggest that histamine plays a
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fundamental role in modulating serotonin during inflammation, thereby providing a novel
therapeutic target as well as providing insights into the neurochemical basis for
depressive illness.
7.2

Introduction
Selective serotonin reuptake inhibitors (SSRIs) are some of the most widely

prescribed class of pharmaceutical agents in the world (The Mayo Clinic, 2019). In the
United States alone, approximately 12% of persons over 12 years old are taking
antidepressants (Pratt et al., 2017). The overarching notion behind this pharmacological
regimen is the monoamine hypothesis of depression (Belmaker and Agam, 2008;
Krishnan and Nestler, 2008). The postulate here is that extracellular serotonin levels are
impaired during depression and by inhibiting the serotonin transporter (SERT), the levels
of this monoamine will be restored. Because the serotonergic underpinnings of
depression remain poorly defined it is not surprisingly that SSRIs suffer from poor
clinical efficacy rates (Artigas et al., 2018). While low efficacy has always been the case
for SSRIs, in recent years the number of SSRI-resistant patients has grown (Greden,
2001). Thus, SSRIs have lost popularity in the research community and researchers are
turning to other means to treat depression including ketamine, psychedelics,
electroconvulsive therapy, vagus nerve stimulation, and deep brain stimulation (Mayberg
et al., 2005; Lisanby, 2007; Shelton et al., 2010; Andrade, 2015; Carhart-Harris et al.,
2016).
There are, however, recent interesting associations between depression and
inflammation that may reinvigorated interest in SSRIs. It is generally well accepted now
that inflammation and depression are comorbidities (Dantzer et al., 2011; Miller and
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Raison, 2016). Additionally, significant relationships have been found between
inflammatory markers in serum and SSRI resistance (Eller et al., 2008; Haroon et al.,
2018). Furthermore, antidepressant treatment has been shown to reduce inflammation
(Kubera et al., 2001; Tynan et al., 2012) and there is some emerging evidence that
inhibiting proinflammatory cytokines can alleviate depression symptoms (Tyring et al.,
2006; Raison et al., 2013; Kohler et al., 2014; Abbott et al., 2015) and increase the
efficacy of SSRIs (Mendlewicz et al., 2006; Barkin et al., 2010). These findings are
exciting but invite many unanswered questions. A critical question here is how does
inflammation affect serotonin neurochemistry and mediate SSRI response? This question
is the focus of this work.
Here we utilize unique electrochemical tools, developed in our lab, for studying in
vivo neurochemistry during a well-established model of acute inflammation
(lipopolysaccharide (LPS) injection) and chronic inflammation (unpredictable chronic
mild stress depression (CMS)). We find rapid and robust decreases in extracellular
hippocampal serotonin (using fast scan adsorption controlled voltammetry (FSCAV)) in
response to i.p. LPS injection or CMS treatment, with no apparent changes in the
functionality of the serotonin release/reuptake system (via fast scan cyclic voltammetry
(FSCV) of evoked serotonin). During this inflammation, we show that an SSRI,
escitalopram (ESCIT), is less effective at increasing the extracellular serotonin levels. We
hypothesize and show that the decreased extracellular serotonin occurs as a consequence
of increased brain histamine in response to the inflammation caused by LPS or CMS. We
show that the ESCIT’s reduced ability to increase serotonin after LPS or CMS is because
of SSRIs’ propensity to also inhibit histamine reuptake. A final experiment highlights, via
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dual pharmacological targeting of both serotonergic and histaminergic systems, that
serotonin levels can be restored to pre-LPS or non-stress control values. This work
implies, on a fundamental chemical level, that it is possibly not yet time to give up on
SSRI therapy, but rather to personalize treatments based on inflammation status.
In this chapter, the work will be broken into two parts. Part I will explore the role
of serotonin and histamine in acute inflammation (LPS model) and part II explore the role
of serotonin and histamine in chronic inflammation (CMS treatment).
7.3

Part I: LPS Impairs SSRI’s Capacity to Increase Hippocampal Extracellular

Serotonin
Neuroinflammation, linked to peripheral inflammation, is commonly associated
with depression-like phenotypes in rodents (O'Connor et al., 2009; Zhu et al., 2010;
Dantzer et al., 2011). In an acute model of inflammation, such as an i.p. injection of LPS,
a robust inflammatory response is marked by increases in pro-inflammatory cytokines
and histamine in the blood (O'Connor et al., 2009; Zhu et al., 2010). In association with
this immune response, rodents start to display ‘sickness behavior’ akin to depression-like
behavior (O'Connor et al., 2009; Zhu et al., 2010; Dantzer et al., 2011). However, the
effect of acute inflammation on brain serotonin remains to be determined. Additionally,
we postulate that LPS-induced increases in peripheral inflammation simultaneously
increases brain histamine (Knigge et al., 1994). Importantly, histamine can regulate
serotonin release via the histamine H3 receptor (H3R) (Schlicker et al., 1988; Threlfell et
al., 2004; Samaranayake et al., 2016). To test the effect of acute LPS-induced
inflammation on brain serotonin and histamine we employ the neurochemical methods
FSCV and FSCAV.
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7.4

Part I: Results

7.4.1

Peripheral Injection of LPS Decreases Extracellular Serotonin Levels in the

Hippocampus
By employing FSCAV to measure ambient hippocampal serotonin, we found that
administration of a low dose of LPS (0.2 mg kg-1, i.p.) caused a rapid decrease in basal
serotonin dropping serotonin from 58 nM to 46 nM (p < 0.001), while saline had no
effect on serotonin concentration (Figure 7.1). Administration of the SSRI, ESCIT (10
mg kg-1, i.p.) to these animals further revealed that animals treated with LPS prior to
ESCIT showed a blunted response to ESCIT. Saline treated animals treated with SSRIs
displayed an increase in ambient serotonin up to 91 nM, significantly increased from
control levels (p < 0.001). LPS treated animals treated with SSRIs also displayed an
increase in ambient serotonin up to 61 nM, significantly increased back to control levels
(p = 0.13), however, basal serotonin rise is still significantly lower in LPS treated animals
compared to saline treated animals both given ESCIT (p < 0.001). Further we find that
the rate of increase following SSRI administration in basal serotonin is much lower in
LPS pretreated animals (slope: Control: 0.46; LPS: 0.26; p = 0.008). Interestingly, we
saw no difference in the stimulated release post-LPS or saline and ESCIT (Figure 7.1B
and 1C respectively) suggesting that the kinetics of serotonergic system are not altered,
only the extracellular levels.
7.4.2

Brain Histamine Rapidly Increases Upon Peripheral LPS Injection
FSCV measures of evoked hypothalamic histamine allows for the simultaneous

detection of histamine release and resulting serotonin inhibition mediated by H3Rs in real
time (Figure 7.2A). Peripheral administration of LPS at a high dose (1.0 mg kg-1, i.p)
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Figure 7.1: Determining the effect of LPS administration on hippocampal basal 5HT
and SSRI-mediated 5HT increase. (A) The concentration of basal hippocampal 5HT
decreases with the administration of LPS (i.p., 0.2 mg kg-1, n=10, shown in pink) while
vehicle control (i.p., saline, n=10, in blue) have no effect on ambient 5HT.
Administration of ESCIT (i.p., 10 mg kg-1) increases 5HT concentration in both groups.
No differences are seen in (B,C) pre-basal control stimulation (in black) nor (B) post
saline + ESCIT (in blue) or (C) post LPS + ESCIT treatment groups (in pink). SEM is
shown in a lighter color error bars or as shadows around the traces. Stimulation is marked
by a box at 5-7 s.
increased evoked histamine within five min of administration (Figure 7.2B) (Ampmax:
5.8 to 8.8 µM; p= 0.14). This resulted in a mild increased inhibition of serotonin
following LPS (Ampmax: 42 to 51 nM; p=0.21). A low dose shows a similar effect on
histamine although the increase is too small to see a significant change in histamine and
the change in serotonin is negligible (Figure 7.2C).
In Figure 7.3, baseline collection of extracellular hippocampal serotonin was
measured for 30 min prior to administration of either thioperamide (H3R antagonist,
orange) or saline (blue). Following thioperamide, one can observe in Figure 7.3 that
extracellular serotonin begins to decline in comparison to the saline treated animals.
While the concentration of serotonin is not statistically different in thioperamide treated
and saline treated controls, the last 10-30 min following thioperamide administration is
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Figure 7.2: Evoked hypothalamic histamine increases with LPS administration. (A)
An example color plot of HA FSCV is shown marking a histamine event at 0.2 V and a
serotonin event at 0.7 V. A gray bar under the color plot denotes the stimulation from 5-7
s. (B) Evoked hypothalamic histamine control is shown in blue and pink is 5 min post
administration of LPS at a high dose (i.p., 1.0 mg kg-1, n=5). Simultaneous inhibition of
serotonin is also shown (inverted to show decreasing concentration following evoked
histamine). (C) Evoked hypothalamic histamine before (blue) and following a lower dose
of LPS (pink, i.p., 0.2 mg kg-1, n=10) administration.
statistically different from the first 10 min of control sample collection within those
animals (10-20 min post thioperamide: p < 0.01; 20-30 min post thioperamide p < 0.01).

Figure 7.3: H3R antagonism decreases basal hippocampal serotonin.
Following 30 min of baseline serotonin concentration, thioperamide was
administered (i.p., 20 mg kg-1, n=4) and is shown to decrease extracellular
hippocampal serotonin. Control animals were given saline (i.p.) and showed
no change in extracellular hippocampal serotonin (n=10).
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7.4.3

Reuptake of Hypothalamic Histamine is Inhibited by SSRIs
Following neurotransmission, histamine is primarily degraded by histamine N-

methyltransferase (HNMT) (White, 1960; Schayer and Reily, 1973; Pollard et al., 1974;
Takemura et al., 1994). However, there is also evidence of partial reuptake reuptake
(Huszti et al., 1997; Sakurai et al., 2006). Thus, we investigated histamine reuptake via
five monoamine transporter proteins: dopamine transporters (DATs), serotonin
transporters (SERTs), norepinephrine transporters (NETs), organic cation transporters
(OCTs), and plasma membrane monoamine transporter (PMAT). Reuptake mechanisms
from these transporters has been previously noted as “promiscuous” suggesting limited
specificity and a potential opportunity for a histamine reuptake mechanism (Daws, 2009).
Six different transporter inhibitor drugs, GBR 12902 (DAT inhibitor, 15 mg kg-1),
desipramine (NET inhibitor, 15 mg kg-1), ESCIT (SERT inhibitor, 10 mg kg-1),
citalopram (SERT inhibitor, 5 mg kg-1), sertraline (SERT inhibitor, 10 mg kg-1), and
decynium-22 (OCT and PMAT inhibitor, 0.1 mg kg-1) were injected (i.p.) into different
mice (n=5 each). Histamine and serotonin responses were measured every 10 minutes, for
60 minutes, after drug administration. In Figure 7.4 we show control signals in blue and
60 min post drug in green. We find that inhibition of most transporters, except for DATs,
shows mild increases in histamine or slowing of histamine reuptake as visualized using
FSCV.
7.4.4

Pharmacological Targeting of Both Serotonin and Histamine Increases

SSRIs Ability to Chemically Increase Serotonin During Inflammation
To target the SSRI or inflammation induced increases in histamine, we sought to
decrease extracellular histamine by administering -fluoromethylhistidine (FMH), a
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Figure 7.4: Histamine reuptake is mediated by many monoamine transporters. The
observed effect of monoamine transport-targeting drugs are shown for evoked
hypothalamic histamine. Control evoked histamine is shown in blue and post (A) GBR
12909 (i.p., 15 mg kg-1, n=5), (B) desipramine (15 mg kg-1, n=5), (C) escitalopram (10
mg kg-1, n=5), (D) citalopram (5 mg kg-1, n=5), (E) sertraline (10 mg kg-1, n=5), or (F)
decynium-22 (0.1 mg kg-1, n=5) is shown in green. Stimulation is marked by the gray box
below at 5-7 s.
suicide histidine decarboxylase inhibitor. In Figure 7.5A we show that 50 min post FMH
administration (i.p., 20 mg kg-1) we see a decrease in the amplitude of histamine evoked
release in the hypothalamus (from 9.3 to 6.4 µM; p = 0.08). Additionally, this decrease in
histamine resulted in a decrease in the inhibition of serotonin, or an overall increase in
serotonin, although this change is not statistically significant (from 42.8 to 38.6 nM; p
=0.59). FSCAV was used to observe the effect of FMH on ambient hippocampal
serotonin (Figure 7.5B). We see that FMH administration increases extracellular
serotonin rapidly at a rate similar to that of ESCIT administration (i.p., 10 mg kg -1).
However, FMH does not slow the reuptake of serotonin, like that seen with ESCIT. This
suggests that FMH is increasing extracellular serotonin by a mechanism different than
inhibition of SERT and more likely through modulation of the H3R.
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Figure 7.5: FMH decreases hypothalamic histamine and increases basal serotonin.
(A) Evoked hypothalamic histamine is shown in black and 50 min post administration of
FMH (i.p., 20 mg kg-1, n=4) is shown in purple. (B) Control basal hippocampal serotonin
is shown for 30 min prior to saline treatment and another 30 min post-saline. Mice were
then administered either ESCIT (i.p., 10 mg kg-1, shown in blue, n=10) FMH (i.p., 20 mg
kg-1, shown in red, n=4). Pre and post-basal stimulated release are shown for both
treatment groups with control in gray and (C) post saline + ESCIT in blue and (D) post
saline + FMH in purple.
Next, we explored the potential of a dual-targeted (histamine and serotonin)
treatment for acute inflammation-induced depression. In Figure 7.6 we show that
combined ESCIT and FMH treatment following LPS administration could increase basal
hippocampal serotonin back to that seen with control (saline + ESCIT) treated animals
(from 61 to 92 nM; p = 0.003). Here, we suggest that combined treatment (ESCIT +
FMH) more rapidly increases extracellular serotonin slope (0.51; p = 0.016) and
overcomes the LPS-induced decreases in ambient serotonin and we postulate that this is
likely due to the two mechanisms of serotonin increase (1. inhibition of SERT by ESCIT,
2. FMH-induced decreases in histamine resulting in decreased H3R-mediated inhibition
of serotonin).
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Figure 7.6: The effect of dual targeting of histamine and 5HT on hippocampal
5HT. (A) In blue, we show saline and ESCIT (i.p., 10 mg kg -1, n=10) treated
controls only show an increase in basal hippocampal serotonin in response to
ESCIT. In pink, we show that LPS (i.p., 0.2 mg kg -1, n=5) decreases extracellular
serotonin and that ESCIT (i.p., 10 mg kg-1, n=5) increases serotonin. In purple, we
show again that LPS (i.p., 0.2 mg kg-1, n=5) decreases extracellular serotonin and
that dual targeting with ESCIT (i.p., 10 mg kg-1) and FMH (i.p., 20 mg kg-1) rapidly
increases serotonin (n=5).
7.5

Part I: Discussion

7.5.1

Brain Serotonin is Lower in Response to Acute Inflammation
There is a robust connection between inflammation and depression (Dantzer et al.,

2011; Miller and Raison, 2016) and increases in chronic inflammatory diseases
associated with increased risk of developing depression means that there is a growing
population of individuals with inflammation-associated depression. For example,
increasing obesity rates (Carey et al., 2014; Abarca-Gómez et al., 2017) and increasing
cancer rates (Bray et al., 2018) correlates to increasing comorbid obesity or cancer
depression. LPS is a well-established acute inflammation model employs a molecule
form the outer membrane of a gram-negative bacteria (O'Connor et al., 2009; Zhu et al.,
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2010). Importantly, injecting even a low dose of LPS increases pro-inflammatory
cytokines and induces sickness-like behavior akin to a depressive like phenotype
(O'Connor et al., 2009; Zhu et al., 2010). It is clear, that the effects of LPS are found in
the brain, however, LPS itself does not cross the blood brain barrier (BBB). It is instead
suggested that LPS impairs the integrity of the BBB (Varatharaj and Galea, 2017) or
induces changes in the brain via increased production of pro-inflammatory cytokines or
activation of the vagus nerve pathway (Borovikova et al., 2000; Meneses et al., 2016;
Somann et al., 2019).
Here we use FSCV and FSCAV, developed in our lab, to measure serotonin in the
mouse hippocampus after acute LPS injection. I found that the evoked serotonin release
does not change (data not shown). The evoked release measures the system’s ability to
release and reuptake serotonin as a function of serotonin synthesis, packaging,
autoreceptor control of release and reuptake. However, none of processes exhibit changes
in response to LPS, thereby suggesting that functionally nothing about the serotonin
system itself is different following LPS. This differs from previous works by Zhu et al.
which found LPS-induced increases in SERT activity (Zhu et al., 2006; Zhu et al., 2010).
We postulate that there may be some mechanism that makes this change in activity
undetectable via our measurements such as fluctuating SERT number in response to LPS
or compensation to the aphysiological electrical stimulation required for FSCV
measurements in vivo. We used FSCAV to explore the more subtle effects of LPS
administration on ambient hippocampal serotonin levels in the absence of stimulation. I
found robust decreases in extracellular serotonin after LPS administration that were
absent in the saline vehicle controls (Figure 7.1). This is very interesting because LPS,
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itself, does not cross the BBB and the effects are very rapid. Importantly, ESCIT
administration 60 minutes after LPS or saline administration shows that the ability of this
SSRI to increase extracellular serotonin is significantly impaired following LPS
treatment. Importantly, ESCIT still inhibited serotonin release as no significant
differences are found in the reuptake rate of serotonin between saline and ESCIT and
LPS and ESCIT using FSCV post basal analysis (Figure 7.1B,C).
This observed decrease in ambient hippocampal serotonin could be due to
increased reuptake by SERTs as seen by Zhu et al. (Zhu et al., 2010) that are hard to
assess with the sledgehammer that is the electrical stim employed for FSCV
electrochemical detection of serotonin which has previously shown to primarily captures
uptake 2 (DATs, NETs, OCTs) (Wood et al., 2014). This does, however, neglect to
account for histamine/H3R-mediated serotonin modulation which is particularly
important to consider with an inflammation model like LPS administration. Thus, we
next explore the effects, of LPS on brain histamine.
7.5.2

During Acute Inflammation, Brain Histamine Inversely Modulates Serotonin
Histamine is a well-known chemical mediator of inflammation in the periphery,

where it is released by immune cells in immune challenges (Rocklin, 1976; Schwartz et
al., 1980). Histamine’s roles in the immune response are so well established in fact that a
frontline treatment to reduce the negative symptoms of immune reactions are
antihistamines, post synaptic H1R antagonists (Kalpaklioglu and Baccioglu, 2012).
Histamine exists in the brain, but much less is known about it. It acts as a
neuromodulator being released from neurons (Watanabe et al., 1983; Panula et al., 1984).
The Hashemi lab and others have shown that histamine release inversely modulates
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serotonin via inhibitory H3 heteroreceptors on serotonin terminals (Schlicker et al., 1988;
Threlfell et al., 2004; Samaranayake et al., 2016). This messenger, however, is likely to
also be involved in the brain’s immune reactions since it is also stored in microglia
(Rocha et al., 2014) and the BBB becomes permeable to histamine containing mast cells
during inflammation (Esposito et al., 2001). Thus, we utilized an FSCV method
developed in our lab to simultaneously measure serotonin and histamine in the posterior
hypothalamus (histamine cell body region) before and after peripheral LPS injection and
found that evoked histamine rapidly increases the amplitude of evoked hypothalamic
histamine in the brain following high dose LPS (1 mg kg-1), but not low dose LPS (0.2
mg kg-1) administration (Figure 7.2).
While the source of the increased histamine remains to be determined, FSCV
measurements observes axonal stimulation, thus it is likely neuronal. Therefore, we
postulate that a high dose LPS administration is either increasing histamine
synthesis/packaging or decreasing stimulation threshold. At low dose, this effect is less
significant but trends towards the same effect. Of note, we postulate that this increase in
histamine directly decreases serotonin via H3R-mediated inhibitory control. To test this,
we inhibited H3Rs and measured ambient serotonin and determined if thioperamide
could decrease basal serotonin in the hippocampus in support of our hypothesis.
The Hashemi lab has previously shown that stimulated neuronal histamine release
and extent of serotonin inhibition before and after H3R antagonism with thioperamide
(Samaranayake et al., 2016). It is of note, that this pharmacological challenge is a
complicated one to interpret since H3 autoreceptors on histamine neurons serve to inhibit
histamine release (thereby reducing histamine inhibition of serotonin, increasing
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serotonin) and H3 heteroreceptors on serotonin terminals serve to inhibit serotonin
release. Therefore, inhibition of H3 receptors will have contradictory effects on serotonin
based on competition between histamine’s inhibitory effects on H3 heteroreceptors vs.
thioperamide’s antagonism of this inhibition. This effect was dose dependent and that at
high doses of thioperamide, histamine’s inhibitory effects on H3 heteroreceptors were
dominant such that at high thioperamide doses histamine-mediated serotonin inhibition
was potentiated (Samaranayake et al., 2016).
Here, we utilized a high dose of thioperamide and observed that ambient
hippocampal serotonin levels decreased, verifying that H3Rs serve to inhibit serotonin
release (Figure 7.3). A further point of note is that thioperamide has affinity for
inhibitory H4R on glial and mast cells, which could also account for the decrease in
ambient serotonin as a function of increased extracellular histamine (Nakamura et al.,
2000).
Thus far, we have found and discussed that serotonin levels are decreased
following LPS administration due to increases in histamine in response to LPS via H3R
and H4R. We also found that after LPS, ESCIT was less effective at increasing ambient
serotonin levels, we next investigate this phenomenon in the context of histamine
reuptake.
7.5.3

SSRI Administration Simultaneously Inhibits Serotonin and Histamine

reuptake and Blunts SSRI’s Ability to Increase Serotonin Levels
Histamine is vesicularly released into the synapse and while there is evidence for
partial histamine uptake into synaptosomes (Barnes and Hough, 2002; Sakurai et al.,
2006) and astrocytes (Huszti, 1998, 2003), a transporter for histamine has never been
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identified (Hough, 1988; Brown et al., 2001). It is rather said to be primarily
enzymatically degraded by histamine n-methyltransferase (HNMT) (White, 1960;
Schayer and Reily, 1973; Pollard et al., 1974; Takemura et al., 1994). However, HNMT
is exclusively expressed intracellularly (Nishibori et al., 2000) thus there must be a
transport mechanism for histamine. Indeed, the Hashemi lab first described the dual
histamine/serotonin measurement, when mathematically describing the responses, our
models necessitated an active reuptake term to capture histamine clearance
(Samaranayake et al., 2016).
We know that monoamine transporters are not particularly selective for their
intended monoamine and as such SERTs, NETs, and DATs regularly uptake many
biogenic amines (Daws, 2009). In this work, we sought to pharmacologically test whether
inhibition of other monoamine transporters affected histamine reuptake. We inhibited
SERTs (with three different agents), DATs, NETs and OCTs/PMTs. Our results do not
definitively identify which transporter is responsible for uptaking histamine because the
different agents have affinity for the different monoamine transporters, but of these
agents, all that have antidepressant activity (sertraline, escitalopram, citalopram,
desipramine, and D-22) inhibit histamine reuptake. Therefore, it is critical that we realize
that the agents tasked with increasing serotonin levels (antidepressants including SSRIs)
also increase histamine. We hypothesize that during inflammation, where increased
histamine levels are already contributing to decreased serotonin levels, this effect
counteracts the SSRIs intended mode of action. We next test this hypothesis by reducing
histamine synthesis during inflammation.
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7.5.4

Dual Pharmacological Targeting of Serotonin and Histamine Restores SSRIs

Chemical Efficacy During Acute Inflammation
We sought to decrease the effect of histamine on H3 heteroreceptors on serotonin
terminals during inflammation. Antihistaminergic agents such as the postsynaptic H1R
and H2R antagonists described above do not have substantial affinity for H3Rs and are
therefore not appropriate for this experiment. In fact, H3R are not an ideal
pharmacological target themselves because of contradictory effects of antagonism (as
described above for thioperamide). Thus, we chose to globally lower histamine levels by
inhibiting histamine synthesis at the molecular level. We administered FMH, a suicide
inhibitor of histidine decarboxylase (the histamine synthesizing enzyme). Many studies
have shown that this can dramatically decrease both peripheral and CNS histamine
rapidly following administration (Garbarg et al., 1980; Maeyama et al., 1982; Watanabe
et al., 1990). Indeed, we confirm that evoked hypothalamic histamine release is blunted
following administration of FMH (Figure 7.5A). Thus, to test our hypothesis that during
inflammation, SSRI induced increases in histamine levels counteract SSRI induced
increases in serotonin, we co-administered the SSRI with FMH after LPS and compared
it to controls where LPS was not administered. We found, strikingly that FMH fully
reversed the LPS induced deficits in SSRI ability to increase serotonin levels. FMH
administration under non-inflammation conditions serves to increase serotonin levels at
the same rate as SSRI given its completely different mode of action (Figure 7.5B).
This neurochemical finding must be put into a behavioral context to draw clinical
conclusions, however, there is a suggestion here that histamine is a key player in the
SSRI process that has thus far not been adequately addressed. Some studies have
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suggested a role for brain histamine in antidepressant treatment and, in this work, we
further probed this connection and solidified the link between histamine and serotonin in
acute inflammation (Knigge et al., 1994; Munari et al., 2015).
7.6

Part II: CMS Impairs SSRI’s Capacity to Increase Hippocampal

Extracellular Serotonin
A common depression model, unpredictable chronic mild stress (CMS) (Willner,
1997), is also associated with inflammation on a chronic timeline (Liu et al., 2015; Lu et
al., 2017; Wang et al., 2018). Rodents that undergo a CMS paradigm display increased
plasma pro-inflammatory cytokines, increased neuroinflammatory markers, and
behavioral changes associated with depression (Liu et al., 2015; Lu et al., 2017; Wang et
al., 2018). We predict that this inflammation is marked by changes in both peripheral and
CNS histamine. Due to histamine’s ability to modulate serotonin via the H3R, we further
predict that this increase in histamine may inversely modulate serotonin in CMS-treated
mice (Schlicker et al., 1988; Threlfell et al., 2004; Samaranayake et al., 2016).
7.7

Part II: Results

7.7.1

Part II: Decreased Serotonin Marks Depression-like Phenotypes in Stress

and Inflammation Models
To study chronic inflammation, we employed a mouse model of chronic mild
stress. This depression model is marked by prevalence of depression-like phenotypes and
peripheral inflammation. Here, a CMS paradigm was used, including 16 weeks of mild
stressors, a battery of behavioral tests, neurochemical analysis, and analysis of
inflammatory markers (schematic of paradigm/experiment in Figure 7.7A). Analysis of
serotonin in CMS-treated mice revealed that there was no difference in evoked serotonin
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in the hippocampus (Figure 7.7B,C,E), however, using FSCAV we were able to show a
difference in basal or ambient serotonin in this region (Figure 7.7D,E). Next, we
analyzed behavioral tests for anxiety (elevated zero maze; EZM) and depression (tail
suspension test; TST). CMS-treated mice showed spent significantly more time in the
closed arm of the EZM than control mice, an indicator of anxiety (p < 0.001) (Figure
7.7F). Using the tail suspension test we found that CMS-treated mice trended towards an
increase in percent of time immobile, an indicator of depressive-like behaviors in the TST
(p = 0.38) (Figure 7.7G). Next, we analyzed cytokines from the plasma of these CMS
and non-stress control mice. For this analysis, we found it best to separate male and
female mice as we analyzed the tissue separately and found distinctly different results by
sex. We found that there was little difference in most peripheral cytokine concentration
between these two groups, however, when the ratios of proinflammatory cytokines to
anti-inflammatory cytokines were compared for example with TNF- / IL-4 in females
we could start teasing out differences (p = 0.01) (Figure 7.7H). CMS-treated mice also
trended towards an increase in IL-6/IL-4 ratios (p =0.21 and 0.24 in male and female
mice) (Figure 7.7I). In this CMS model, it appears that extracellular serotonin is a robust
marker, but nothing functionally has changed about the serotonin system as shown by the
conserved evoked release in CMS and non-stress control mice. Inflammation and
behavioral testing serve to further confirm our model. Moving forward, we target a
molecule that modulates serotonin and is linked to inflammation, histamine.
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Figure 7.7: Neurochemical, behavioral, and inflammatory changes following CMS
treatment. (A) A schematic is shown for the 16-week CMS paradigm used as well as
behavior, neurochemical, and inflammation studies that followed. (B) An example color
plot for hippocampal serotonin is shown with the serotonin event found at 0.7 V.
Stimulation is marked by the box below at 5-7 s. (C) The average evoked hippocampal
serotonin signal for non-stress control (in blue) and CMS mice (in gray). SEM is shown
as a lighter color around the trace. (D) Each animal as well as average basal hippocampal
is shown for control (in blue) and CMS mice (in gray). The average is shown in the
darkest color. (E) A table with tabulated maximum amplitude and t1/2 of evoked serotonin
release as well as extracellular serotonin is shown. (F) average time in closed area of
elevated zero maze (EZM). (G) Average percent immobility in the tail suspension test
(TST). (H,I) Analysis of cytokine ratios (TNF-/IL-4 and IL-6/IL4 respectively).
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With CMS treatment, we observed a very mild increase in evoked hypothalamic
histamine release and decreased control over the resulting serotonin inhibition, although
this change was not statistically significant (Figure 7.8E). Overall, increased histamine
could explain the decrease in extracellular serotonin. Thus, we designed an experiment in
which three groups of animal treatments were applied: non-stress control treated with
ESCIT (10 mg kg-1, i.p.), CMS mice treated with saline then ESCIT (10 mg kg-1, i.p.),
and CMS mice co-administered ESCIT (10 mg kg-1, i.p.) and a histamine synthesis
inhibitor (FMH, 20 mg kg-1, i.p.) (Figure 7.8B). CMS animals started with a lower level
of extracellular serotonin and when ESCIT was administered serotonin increased in both
groups but the rate of increase and end level of serotonin was much lower in CMS mice.
To address the possible role of inflammation in this response, we co-administered ESCIT
and a FMH to a new cohort of CMS mice. In these mice, we saw that ambient serotonin
increased faster and to a level comparable to a control mouse.

Figure 7.8: Dual targeting of histamine and 5HT effects on hippocampal 5HT in
CMS-treated mice. (A) Evoked hypothalamic histamine is shown in black for control
and blue for CMS-treated mice. (B) Basal hippocampal serotonin in control mice given
saline and then ESCIT (i.p., 10 mg kg-1, n=5, in blue), CMS-treated mice given saline and
then ESCIT (i.p., 0.2 mg kg-1, n=5, in gray), and CMS-treated mice given saline and then
ESCIT (i.p., 10 mg kg-1) and FMH (i.p., 20 mg kg-1, n=5) in purple.
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7.8

Part II: Discussion

7.8.1

Brain Serotonin is Lower in Response to Chronic Inflammation
It is well documented that CMS treatment increases the risk for depressive-like

behaviors (Willner, 1997). However, it is also associated with peripheral and, therefore,
likely neuroinflammation (Liu et al., 2015; Lu et al., 2017; Wang et al., 2018). As such,
we employ this model as a chronic inflammation-associated depression model. Here we
find that CMS-treated mice display a similar response in extracellular hippocampal
serotonin to treatment that LPS treatment induces. CMS treated mice show decreased
extracellular serotonin, below that seen in non-stress controls. In fact, basal serotonin in
CMS mice is not statistically different than that of LPS treated mice suggesting that the
serotonin system is similarly altered by both disease states. Importantly, this similar
concentration highlights the tight regulatory control ability that the serotonin system has
in order to maintain homeostatic balance, as previously noted (Hashemi et al., 2012).
Next, we aim to determine if histamine is similarly altered in these CMS-treated animals.
7.8.2

Dual Pharmacological Targeting of Serotonin and Histamine Restores SSRIs

Chemical Efficacy During Chronic Inflammation
We employed FSCV to determine, that while not significant, CMS mice did trend
towards an increased evoked hypothalamic histamine concentration. Importantly, this
was not dramatically increased following LPS either suggesting that evoked histamine
has only a mild response to inflammation and that chronic inflammation may induce
compensatory mechanisms to return proper evoked release. Further, we postulate that
elevated inflammation (and potentially elevated basal histamine levels) could mediate the
lower extracellular hippocampal serotonin levels seen in CMS-treated mice. Thus, we
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aimed to determine how SSRIs would affect these systems. CMS-treated mice show
marked increases in ambient serotonin following ESCIT administration, however,
because they start at a lower concentration the resulting ambient serotonin is much lower
than that of non-stress control mice treated with ESCIT. In fact, following ESCIT, CMStreated mice show extracellular serotonin levels akin to that of the baseline levels seen in
non-stress controls. Next, coadministration of ESCIT and FMH induced robust increases
in ambient serotonin (akin to that seen following LPS in Figure 7.6). Thus, we postulate
that dual targeting of histamine and serotonin could increase extracellular serotonin and
ameliorate the impaired SSRI-induced increases in serotonin seen in CMS-treated mice.
Importantly, we show strikingly similar responses of dual histamine and serotonin
targeting in both acute and chronic inflammation-associated depression models and
suggest that histamine may play a crucial role in serotonin dynamics as well as response
to SSRI in these disease states.
7.9

Conclusion
SSRIs are prescribed widely and aim to increase extracellular serotonin levels,

under the assumption that during depression these levels are aphysiologically low.
However, these pharmaceutical agents do not have good clinical efficacy, turning
researchers to other therapies. Yet new emerging evidence implies that the inflammatory
state may dampen SSRIs clinical abilities. Here, we took a fundamental approach to this
idea by measuring serotonin with fast electrochemical tools after an acute and chronic
inflammation challenge. We concluded that inflammation in mice decreased hippocampal
extracellular serotonin. We found that this reduction in serotonin was due to enhanced
H3R heteroinhibition as a consequence of increased inflammation-induced brain
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histamine. We showed that LPS and CMS impaired an SSRI’s capacity to increase
extracellular serotonin because of this SSRIs’ off-target inhibition of histamine reuptake.
This effect could be reversed via inhibition of histamine synthesis. Our work shows that
histamine’s ability to modulate serotonin and SSRI’s actions on serotonin are important
factors to consider for not only understanding the biochemical basis of depression, but
also for improving clinical efficacy of existing SSRIs.
7.10
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8.1

Abstract
Epidemiological studies estimate that over 60% of the US population may be

categorized as overweight/obese. The complications of obesity extend to the central
nervous system (CNS), including an increased incidence of neurological comorbidities
like depressive illness. We and others have reported that rodents with an obesity
phenotype exhibit depressive-like behaviors and increases in pro-inflammatory cytokines.
Given the hypothesized role of serotonin in the pathogenesis of depression, serotonin in
the CNS may also be dysregulated in obesity-induced depression, which could account
for decreased efficacy of selective serotonin reuptake inhibitors (SSRIs), including
escitalopram, within the obese population. Using fast-scan cyclic voltammetry, the
current study determined that the SSRI, escitalopram was less effective in slowing
serotonin reuptake in the hippocampus of obese rats, deficits that are accompanied by
neuroinflammation and increased expression of SERTs. These results provide real-time
assessment of neurochemical deficits in serotonergic synapses, thereby providing a
neurochemical basis for comorbid depression in obesity.
8.2

Introduction
The global rate of adult obesity has nearly doubled since the 1980’s, and now

affects a staggering 650 million people (World Health Organization, 2018b), making it a
pertinent healthcare issue with profound socioeconomic effects. There is a growing
appreciation that the complications of obesity extend to the central nervous system (CNS)
and result in increased risk for neurological co-morbidities like depressive illness.
Depressive illness has overlapping epidemiology symptoms and therefore likely has
overlapping pathophysiology with obesity (Rosmond, 2004; Simon et al., 2006; Luppino
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et al., 2010). Independently, depression illness is the leading causes of disability
worldwide and impacts more than 300 million people (World Health Organization,
2018a). While the neurochemical basis of depressive illness remains to be fully
elucidated, many antidepressants target the serotonergic system. One such group of
antidepressants, SSRIs, including escitalopram (ESCIT), are less efficacious among
individuals with higher body weights or increased levels of inflammation, both of which
are associated with obesity (Papakostas et al., 2005; Argel Aguilar-Valles 2015).
However, the neurobiological underpinnings responsible for the increased rate of
depression in obesity, as well as the mechanistic basis for the decreased efficacy of SSRIs
in obese patients are not fully understood.
Obesity is characterized by chronic low-grade inflammation and it is theorized
that this inflammation results from macrophage infiltration into adipocytes during the
development and progression of obesity (Argel Aguilar-Valles 2015; Reus et al., 2015).
The inflammation-associated increases in pro-inflammatory cytokines exert deleterious
effects in the central nervous system (CNS), and are postulated to contribute to the
development of depression and other psychiatric disorders (Reus et al., 2015).
Mechanistically, pro-inflammatory cytokines are proposed to decrease serotonin (5HT)
synthesis in the raphe nucleus (RN) (Müller and Schwarz, 2007) and regulate serotonin
transporter (SERT) number and function (Zhu et al., 2006; Malynn et al., 2013).
Collectively, these theories provide a potential neurochemical basis for the decreased
efficacy of SSRIs in obese individuals with comorbid depression relative to non-obese
patients with depression.
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Inflammation is proposed to decrease serotonin levels and SSRI responsiveness in
the brain, despite this the hypothesis has never been directly addressed. As such, the
current study directly examined the connection between obesity, inflammation, and
depression while identifying the deficits in ESCIT activity in obese rats. For the first
time, FSCV/FSCAV was used to fully characterize the local hippocampal serotonergic
system in obese animals with exceptional temporal resolution. Evaluation of an acute
ESCIT administration and resulting neurochemical changes are essential to understand
how these antidepressants exert their pharmacological effects. By teasing out any
differences in the neurochemical response to ESCIT in both control diet fed and high fat
diet fed rats I aimed to determine why ESCIT may not be effective in obese populations.
The given study has profound implications for understanding pharmacological properties
of SSRIs and how disease states can alter these properties affecting the efficacy of
antidepressants.
8.3

Results

8.3.1

Development of an Obesity Phenotype Correlates to the Emergence of

Depressive-like Behaviors
Pilot data collected using control and hypothalamic-IRAS rats revealed an
interesting phenomenon that we further explore in this work (Figures C.1-3). We found
that obese animals (hypo-IRAS) showed decreases extracellular hippocampal serotonin
(Figure C.1) and decreased fluoxetine-induced slowing of serotonin reuptake in the
hippocampus (Figure C.2). Further, we probed the serotonergic system using FSCV and
preliminary data suggested that obese animals had blunted responses to SSRIs as marked
by decreased ability of SSRIs to slow serotonin reuptake (Figure C.3). This spurred the
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current studies to explore the role of serotonin in obesity-induced depression. In these
experiments, I employed a model of high fat diet in male Sprague Dawley rats (Figure
8.1A). High fat diet is well accepted to contribute to the growing rates of human obesity
and is therefore commonly employed as an obesity model in rodents. Further, rodent
models of obesity animals have been shown by us and others to increase the development
of depressive-like behaviors (Grillo et al., 2011; Sharma and Fulton, 2013; Zemdegs et
al., 2016). Animals were randomly selected into control (15% kcal from fat) or high fat
diet (45% kcal from fat) treatment groups. Following 16 weeks on their respective diets,
behavioral, endocrine, and neurochemical studies were completed (Figure 8.1A). The
rats that were fed the high fat diet separated into two distinct biological groups depending
on if they did or did not gain weight (determined by body weights above or below the
average control diet-fed rat’s body weight) (Figure 8.1B). These groups were named the
diet induced obesity (DIO) and diet resistant (DR) groups respectively. DIO rats
displayed increased body weight and plasma leptin compared to control-diet fed animals
suggesting a full obesity phenotype (Figure 8.1B,C). There were no significant
differences in plasma triglycerides between the groups (Figure 8.1D). The DR animals
did not show the weight gains and elevated leptin associated with obesity but had mild
increases in plasma leptin suggesting DR animals displayed altered metabolic states
(Figure 8.1B,C). Further sucrose preference tests revealed that depressive-like anhedonic
behaviors were present in both groups fed high fat diet compared to control-chow fed
animals (Figure 8.1E).
8.3.2

Obesity Phenotype Correlates to Impaired Serotonin Neurochemistry
FSCV and FSCAV were employed in the hippocampus of live, anesthetized rats
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Figure 8.1: High fat diet fed rats develop obesity and depressivelike phenotypes. (A) The paradigm for diet treatment and behavioral,
biological, and neurochemical studies is shown. (B) Body weight gain
for controls, DR, DIOs each week of dietary treatment show
significant weight gain in DIOs over controls and DR rats. (C) Plasma
leptin is elevated in DIO rats. (D) Plasma triglycerides are shown for
control, DR, and DIO rats. (E) Percent sucrose water consumed over
total consumption (% sucrose) is shown for control, DR, and DIO
animals, again with DIO animals being significantly different from
that of the other two groups. Significance was determined using an
ANOVA.
to examine how serotonin neurochemistry may be altered in obesity and thereby
contributing to the development of depressive-like behaviors. A schematic of FSCV
hippocampal serotonin analysis is shown in Figure 8.2A. An example of a generated
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color plot is shown in Figure 8.2B. Neurochemical studies revealed that diet does not
change control evoked hippocampal serotonin release (FSCV) nor extracellular levels of
serotonin (FSCAV) (Figure 8.2C-F). However, I did see differences in stimulated release
following administration of the SSRI, escitalopram (ESCIT, i.p., 10 mgkg -1). Percent
inhibition of SERT, determined by change in the slope following ESCIT from the control
reuptake slope of the reuptake curve, is significantly lower in DIO animals than that of
controls animals (p = 0.04; Figure 8.2E).
We hypothesized that the changes in neurochemistry seen in Figure 8.2C-F may
be driven by inflammation-induced changes in DRN 5HT production or hippocampal
SERT

levels

and

function.

Prior

studies

hypothesized

that

obesity-induced

neuroinflammation may decrease serotonin synthesis in the DRN (Dantzer et al., 2008).
However, I did not observe increases in pro-inflammatory cytokines in the DRN in
control, DR, or DIO animals (Figure 8.3A-E), nor did I see changes in 5HT
concentration in the hippocampus (Figure 8.2E). These observations suggest that raphe
nucleus synthesis of 5HT is unaffected in DIO rats. Next, assessment of cytokines in the
hippocampus identified a selective increase in IL-1 levels in the hippocampus of DIO
rats (Figure 8.3F-J).
Another hypothesis has suggested that obesity-induced neuroinflammation drives
the expression of SERTs in the CNS (Miller and Raison, 2016) and several studies have
established a mechanistic relationship between neuroinflammation and SERT activity
(Zhu et al., 2005; Zhu et al., 2010; Couch et al., 2013). Accordingly, I examined the
SERT expression and neuroinflammation in the hippocampus of control DR and DIO
rats. Immunofluorescence analysis determined that hippocampal expression of SERTs
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Figure 8.2: ESCIT is less effective at slowing hippocampal 5HT reuptake in obese
rats. (A) A schematic showing carbon fiber microelectrode (working electrode; WE)
placement in the CA2 region of the hippocampus and the stimulating electrode (STIM) in
the medial forebrain bundle (MFB) to stimulate 5HT release from the dorsal raphe
nucleus (DRN) (B) An example of a color plot generated from rat hippocampal serotonin
analysis. The serotonin event is marked by a dotted white line at 0.7 V where the current
vs. time trace was extracted and by a black dotted line where the current vs. voltage was
extracted. Electrical stimulation at 5-7 s is denoted by the gray box below the color plot.
Average control hippocampal evoked release is shown for (C) control diet fed, (D) diet
resistant high fat diet-fed (DR), and (E) diet induced obese high fat-fed rats. (F) A table
showing the analysis of max amplitude, t1/2, % inhibition following SSRI, and basal
hippocampal 5HT is shown.
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Figure 8.3: Cytokine analysis in DRN and hippocampus of high fat diet fed rats.
Average (A) IL-1, (B) IL-1ß, (C) IL-4, (D) IL-6, and (E) TNF- in DRN tissue
homogenates are shown. Average (F) IL-1, (G) IL-1ß, (H) IL-4, (I) IL-6, and (J) TNF in DRN tissue homogenates are shown. Control diet fed animals are shown in blue, DR
in orange and DIO in red. Statistical significance was defined as p < 0.05.
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was significantly elevated in the hippocampus of DIO rats compare to DR rats. Since
prior studies demonstrated that proinflammatory cytokine activation of IL-1 receptors
increases the expression of SERTs. We previously showed that DIO rats exhibit a
selective increase in IL-1 in the hippocampus (Figure 8.3F). Additionally, I determined
that IL-1 receptor signaling, specifically p38 MAPK levels, are increased in DIO rats
compared to DR rats and rats provided a control diet (data not shown). These results
suggest that decreased responsivity to ESCIT may be the result of obesity-induced
increases in hippocampal IL-1 levels and IL-1 receptor activation, which enhances
increased expression of SERTs in the hippocampus of DIO rats.

Figure 8.4: SERT expression is elevated in DIO rats. Microscopy of SERT
immunofluorescence of hippocampal slices from (A) control, (B) DR, and (C) DIO rats is
shown. Intensity of SERT fluorescence is quantified in D. Statistical significance was
defined as p < 0.05.
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8.5

Discussion

8.5.1

High Fat Diet Induces Endocrine and Biological Changes Associated with

Obesity and Anhedonic Behaviors Associated with Depressive-like Phenotypes
Obesity has been shown to be an imbalance in energy intake and energy
expenditure, however, many biological, genetic and environmental factors also play a
role. In animals and humans increased fat intake has directly been correlated with obesity
(Bray et al., 2004). In this study, we find that rats fed a high fat diet do not all develop
obesity in a phenomenon that matches what is seen with humans. This separation
following high fat diet treatment is not novel, as Levin et al. previously identified that
Sprague Dawley rats could be selectively breed for their tendency to gain weight or not
on a high fat diet (Levin et al., 1983; Levin et al., 1997). We find that high fat diet-fed
rats self-divide about 50/50 into DIO and DR groups following treatment with high fat
diet. DIO animals show increases in body weight and plasma leptin when compared to
control diet fed animals suggesting that these animals are developing obesity (Figure
8.1). In DR animals, we see body weight is near that of control animals or mildly
decreased. These DR animals show some mild increases in plasma leptin, although
importantly not as much as that seen in DIO animals (Figure 8.1). Behavioral testing for
the depressive-like phenotype via the sucrose preference test revealed that DIO and DR
animals display anhedonic behavior (Figure 8.1E).
8.5.2

Linking Depressive-like Behaviors Associated with Obesity to Altered

Serotonin Neurochemistry
Using FSCV, I found that evoked and basal hippocampal serotonin are consistent
between control, DR, and DIO animals (Figure 8.2). However, when the serotonergic
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system is challenged with administration of ESCIT I can start to tease out differences.
DIO animals show decreased inhibition of reuptake following SSRIs (Figure 8.2E,F).
This aligns with clinical data showing obese individuals are less likely to respond to
classic antidepressant treatment (Uher et al., 2009; Guo and Lu, 2014).
8.5.3

Elevated Inflammation May Account for Changes in SERT Quantities
One potential explanation for the decreased reuptake slowing following SSRIs in

DIO rats is increased number of SERTs (Figure 8.4). Interestingly, DR animals trend in
the other direction with a mild decrease in SERT which may account for their vastly
different biological responses to high fat diet. Further, our results clearly show that
region-specific changes in hippocampal cytokines, like IL-1, may directly relate to
number and function of SERTs in high fat diet fed rats that gain weight (Figure 8.3).
Other studies have shown increases in pro-inflammatory cytokines following HFD
including in the hippocampus (Guillemot-Legris and Muccioli, 2017). Changes in proinflammatory cytokines are not seen in the raphe nucleus, emphasizing the site-specific
changes that we see only in the hippocampus (Figure 8.3). Further, we go on to show
that changes in p38-MAPK may serve an important link between inflammation and
SERT as was previously shown by Zhu et al. (Zhu et al., 2010). Taken together, this
highlights how dietary changes my alter brain neurochemistry increasing the risk of
depression and contribute to the variable efficacy of SSRIs that we see in these distinctive
groups.
8.6

Conclusion
In conclusion, this work aims to address the neurobiological underpinnings

responsible for the bidirectional relationship between inflammation and depression as
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well as the mechanistic basis for the decreased effectiveness of SSRIs in individuals with
elevated inflammation. My results suggest that obesity may produce neurochemical
changes in SERT level mediated by region specific increases in pro-inflammatory
cytokines. Together, this begins to mechanistically determine why obese individual have
an increased risk of developing depression and are less likely to respond to
antidepressants. A further understanding of the role of high fat diet in these
neurochemical changes will be required. Studies with dietary reversal, antiinflammatories like resveratrol, or exercise may be key to elucidating the mechanism by
which these changes occur.
8.7

References

Argel Aguilar-Valles WI, Christoph Rummel , Giamal N. Luheshi (2015) Obesity,
adipokines and neuroinflammation. Neuropharmacology 12.023.
Bray GA, Paeratakul S, Popkin BM (2004) Dietary fat and obesity: a review of animal,
clinical and epidemiological studies. Physiology & behavior 83:549-555.
Couch Y, Anthony DC, Dolgov O, Revischin A, Festoff B, Santos AI, Steinbusch HW,
Strekalova T (2013) Microglial activation, increased TNF and SERT expression
in the prefrontal cortex define stress-altered behaviour in mice susceptible to
anhedonia. Brain, behavior, and immunity 29:136-146.
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From
inflammation to sickness and depression: when the immune system subjugates the
brain. Nat Rev Neurosci 9:46-56.
Grillo CA, Piroli GG, Kaigler KF, Wilson SP, Wilson MA, Reagan LP (2011)
Downregulation of hypothalamic insulin receptor expression elicits depressivelike behaviors in rats. Behav Brain Res 222:230-235.
Guillemot-Legris O, Muccioli GG (2017) Obesity-induced neuroinflammation: beyond
the hypothalamus. Trends in Neurosciences 40:237-253.
Guo M, Lu XY (2014) Leptin receptor deficiency confers resistance to behavioral effects
of fluoxetine and desipramine via separable substrates. Transl Psychiatry 4:e486.
Levin BE, Triscari J, Sullivan A (1983) Relationship between sympathetic activity and
diet-induced obesity in two rat strains. American Journal of PhysiologyRegulatory, Integrative and Comparative Physiology 245:R364-R371.

172

Levin BE, Dunn-Meynell AA, Balkan B, Keesey R (1997) Selective breeding for dietinduced obesity and resistance in Sprague-Dawley rats. American Journal of
Physiology-Regulatory, Integrative and Comparative Physiology 273:R725-R730.
Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG
(2010) Overweight, obesity, and depression: a systematic review and metaanalysis of longitudinal studies. Arch Gen Psychiatry 67:220-229.
Malynn S, Campos-Torres A, Moynagh P, Haase J (2013) The pro-inflammatory
cytokine TNF-α regulates the activity and expression of the serotonin transporter
(SERT) in astrocytes. Neurochemical research 38:694-704.
Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary
imperative to modern treatment target. Nat Rev Immunol 16:22-34.
Müller N, Schwarz M (2007) The immune-mediated alteration of serotonin and
glutamate: towards an integrated view of depression. Molecular psychiatry
12:988.
Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE,
Rosenbaum JF, Fava M (2005) Obesity among outpatients with major depressive
disorder. Int J Neuropsychopharmacol 8:59-63.
Reus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F,
Quevedo J (2015) The role of inflammation and microglial activation in the
pathophysiology of psychiatric disorders. Neuroscience 300:141-154.
Rosmond R (2004) Obesity and depression: same disease, different names? Med
Hypotheses 62:976-979.
Sharma S, Fulton S (2013) Diet-induced obesity promotes depressive-like behaviour that
is associated with neural adaptations in brain reward circuitry. International
journal of obesity 37:382.
Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, Kessler
RC (2006) Association between obesity and psychiatric disorders in the US adult
population. Arch Gen Psychiatry 63:824-830.
Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, Henigsberg N, Souery D,
Placentino A, Perroud N (2009) Body weight as a predictor of antidepressant
efficacy in the GENDEP project. Journal of affective disorders 118:147-154.
World Health Organization (2018a) Depression Fact Sheet. In: World Health Oranization
World Health Organization (2018b) Obesity and Overweight. In.
Zemdegs J, Quesseveur G, Jarriault D, Pénicaud L, Fioramonti X, Guiard BP (2016)
High‐fat diet‐induced metabolic disorders impairs 5‐HT function and anxiety‐like
behavior in mice. British journal of pharmacology 173:2095-2110.

173

Zhu C-B, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin1beta and tumor necrosis factor-alpha activate serotonin transporters.
Neuropsychopharmacology 31:2121.
Zhu C-B, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD (2005) p38 MAPK
activation elevates serotonin transport activity via a trafficking-independent,
protein phosphatase 2A-dependent process. Journal of Biological Chemistry
280:15649-15658.
Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA (2010)
Interleukin-1 receptor activation by systemic lipopolysaccharide induces
behavioral despair linked to MAPK regulation of CNS serotonin transporters.
Neuropsychopharmacology 35:2510-2520.

174

CHAPTER 9
PERSPECTIVES AND FUTURE DIRECTIONS
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Neuropsychiatric diseases, like depression, affect a large and growing percentage
of the global population. Depression is accepted to be a life-long disease whose treatment
and management is an ongoing challenge for patients, loved ones, and health care
providers. This challenge generates a large financial burden on the global community. An
improved understanding of depression pathology would greatly advance therapeutic
avenues and alleviate this disease burden.
In this work, electrochemistry was employed to probe the brain serotonin and
histamine to improve our mechanistic understanding of depression neurochemistry.
Serotonin was targeted for its long-hypothesized role in depression (see monoamine
hypothesis of depression in Chapter 1) Another neurotransmitter, histamine, was
targeted for its role in inflammation (see cytokine hypothesis of depression in Chapter
1).
In Chapter 3, we probed the serotonin systems of male and female system to
determine that sex-dependent differences only emerged, in the hippocampus, in response
to pharmacological intervention. Female mice exhibited tighter autoreceptor control in
response to acute SSRI administration. Similarly, in Chapter 4, we found that sexmediated differences may account for the tighter H3R-mediated histaminergic control in
the posterior hypothalamus seen in female mice in response to targeted H3R intervention.
In Chapter 5, I employed an SSRI resistant genetic mouse model (SERT
Met172) to improve our understanding of how SSRIs induce biochemical changes to the
biological system. I found that repeated stimulation can alter basal serotonin levels and
that SSRIs have off target effects on VMAT that may account for some increases in
evoked release that I saw following acute SSRI administration in wild type mice.
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In Chapter 6, we conducted dose responses to escitalopram in vivo and in vitro to
determine that acute SSRI administration rapidly enhances SERT reuptake before
inhibiting it.
In Chapter 7 & 8, I explored the link between inflammation and depression
(summarized in Figure 9.1). Using both an acute (LPS-induced) and chronic (CMSinduced) models of depression-like phenotypes in rodents we saw decreased basal
serotonin and blunted responses to SSRIs. Targeted immune treatment using histamine
synthesis inhibitors successfully impaired histamine release, impaired histamine H3Rmediated inhibition of serotonin, and rescued SSRI responsiveness. Taken together this
suggests that dual targeting of histamine and serotonin may be therapeutically beneficial
for depression treatment.

Figure 9.1: The role of acute and chronic inflammation in depression. Both
acute (LPS) and chronic (CMS and obesity) inflammation are associated with
increased inflammatory response and risk of depression/depressive-like behaviors.
As such these inflammatory models were used to explore neurochemical changes
in CNS histamine and serotonin.
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In Chapter 8, I expanded to another chronic model of depression, namely
obesity, which has a high comorbidity with depression. Rats fed a high fat diet naturally
split into diet induced obesity (DIOs; gained weight) or diet resistant (DRs; failed to gain
weight) and responsiveness to SSRIs was impaired only in the DIO animals. Further, we
found that DIO animals had elevated pro-inflammatory cytokines, SERT levels, and p38
MAPK levels.
While we have collectively made great strides in depression research with this
work, I acknowledge that much work remains. This work clearly shows a novel role of
histamine in inflammation associated depression and, further, that histamine may serve as
a potential therapeutic target to alleviate depression in treatment resistant patients. In the
future, I plan to continue to explore the links between inflammation and depression.
Importantly, we hope to expand our studies to human stem cells to more adequately
advance our current understanding of clinical depression and better equip the medical
community to treat it.
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APPENDIX A
CHAPTER 3: SUPPLEMENTAL INFORMATION

Figure A.1: Evoked hippocampal serotonin in young and old adult mice. (A) The raw
data for evoked serotonin response in young adult mice (aged 6–8 weeks, n = (11
females, 3 males) = 14 mice total) and (B) adult mice (aged 9–12 weeks, n = (3 females,
5 males) = 8 mice total) are shown in purple and green respectively. (C) A table with the
average maximum amplitude and t1/2 are shown, neither of which are statistically between
the two age groups.
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Figure A.2: Representative estrous cycle images. A representative cell sample
pictomicrograph is shown for each of the estrous cycles: (A) estrus, (B) metestrus,
(C) diestrus, and (D) proestrus. Estrus contains anucleated cornified cells, metestrus
contains cornified, nucleated epithelial cells, and leukocytes, diestrus contains
leukocytes and proestrus contains nucleated epithelial cells. Methods and analysis
were completed as described in (Caligioni, 2009).
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Figure A.3: Averaged male and female evoked prefrontal cortex serotonin.
Female (red) serotonin responses (n= 5) in the medial prefrontal cortex (mPFC) are
compared to previously reported male (blue) serotonin response (n = 20). Error bars
for every tenth file are shown in similar corresponding colors. The wide error bar
range results from single and double peak signals being averaged together as well as
the low n size in the case of the females. Nonetheless, the error bars suggest that
there is no difference in male and female serotonin signals in the mPFC.
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APPENDIX B
CHAPTER 5: SUPPLEMENTAL INFORMATION

Figure B.1: Met172 mice still show slowed 5HT reuptake following paroxetine
administration. (A) Control evoked 5HT (gray) and 60 min post paroxetine (green, 10
mg kg-1) are shown for WT (n=4) and (B) Met 172 mice (n=3).
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APPENDIX C
CHAPTER 8: SUPPLEMENTAL INFORMATION

Figure C.1: Hippocampal basal serotonin efflux
in control and hypo-IRAS rats. The average
concentration of serotonin efflux collected via
microdialysis in the hippocampus of control rats
(nonsense lentivirus) and rats treated with the IRAS
virus.
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*

Figure C.2: Fluoxetine-stimulated hippocampal
control and hypo-IRAS rats. We show the average
percent baseline for each animal with four 15 min
collections prior to administration of fluoxetine (i.p.,
additional post treatment 15 min sample collections.
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serotonin efflux in
hippocampal efflux as
bassline microdialysis
10 mg kg-1) and eight

Figure C.3: Preliminary FSCV analysis of serotonin in control and hypoIRAS rats given fluoxetine: Example color plots of hippocampal serotonin
analysis via FSCV are shown for (A) control and (B) hypo-IRAS animals.
Serotonin is marked by a dotted white line at approximately 0.7 V and stimulation
is marked by a green box below (5-7 s). Example color plots for (C) control and
(D) hypo-IRAS animals post-Fluoxetine (90 min post, i.p., 10 mg kg-1). In (E) for
control rats and (F) for hypo-IRAS rats you the average current vs. time trace is
shown for control and 90 min post-fluoxetine evoked hippocampal release.
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APPENDIX D
PERMISSION TO REPRINT: CHAPTER 1

Recent Developments in Carbon Sensors for At-Source Electroanalysis
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APPENDIX E
PERMISSION TO REPRINT: CHAPTER 2 & 3

In Vivo Serotonin Dynamics in Male and Female Mice: Determining Effects of Acute
Escitalopram Using Fast Scan Cyclic Voltammetry
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